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1. INTRODUCTION 
The World Health Organisation (WHO) has recorded 31.8 million [30.1 million – 33.7 
million]  adult patients as infected with the Human Immunodeficiency Virus (HIV) 
with 1.9 million [1.7 million – 2.1 million] people diagnosed for the first time, as per 
the global summary of the AIDS epidemic (2013).(1) As is evident from these figures, 
HIV/AIDS still remains a vital global health issue. The National AIDS Control 
Organisation (NACO) statistics reveal that India has the third highest number of 
people infected with HIV in the world. The prevalence has been projected to be 
approximately 20.89 lakh, with 0.27 %  in the adult age group (15-49 years) in 
2011.(2) 
 
Highly active antiretroviral therapy (HAART) is essential for management of patients 
with HIV infection. The EuroSIDA study compared the early ART period to pre-ART 
and later ART treatment periods, and showed a reduced mortality and progression to 
AIDS on continuous ART. Widespread use of ART has resulted in a marked decline 
in the incidence of most AIDS defining conditions and mortality both in the developed 
and developing world.(3) Suppression of HIV replication is essential to prevent HIV 
associated morbidity and mortality; it also improves the quality of life in patients with 
HIV infection. Strict adherence to antiretroviral therapy is required for adequate 
suppression of HIV infection.(3)  
 
16 
 
ART has been dispensed free of cost under the National AIDS Control Programme 
(NACP II) since April 2004. More than 300 ART centres are functional in India at 
present and more than 516,000 patients are receiving ART at these centres. 
Approximately 30,000 patients receive free ART in the private sector.(4) 
Consequently, there has been a progressive decline in annual AIDS related mortality 
with approximately 1,50,000 lives being saved due to ART till 2011.(2) 
 
Despite adequate treatment with ART, excess mortality has been observed in these 
individuals as compared to matched controls and is not explained by parameters like 
CD4 count alone. Studies like the SMART trial point towards probable  etiologies 
such as  HIV-associated inflammation with increased risk of hypercoagulability and 
aging-associated organ system injury.(5)There has been an increasing body of 
evidence suggesting that the risk of serious non-AIDS conditions like cardiovascular 
disease (CVD), renal or hepatic disease and non-AIDS defining malignancies is 
increased in people with HIV infection as compared to matched controls.(6) Multiple 
trials have been conducted to assess correlation of non-traditional with traditional 
markers of inflammation to monitor patients with potentially modifiable risk factors. 
 
Physicians treating patients with HIV infection are frequently asked for prognostic 
assessments and quality of life after initiating therapy. Prognostic systems such as risk 
factors, staging systems, statistical models, and computer algorithms have been 
developed to standardize and enhance the accuracy of prognostic assessments. The 
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Veterans Aging Cohort Study (VACS) Risk Index was designed to predict mortality 
in HIV patients who have been treated for one year, using a simple scoring system. It 
was intended  to take into account all possible effects of HIV disease, comorbidities, 
substance abuse, and adverse drug reactions secondary to treatment, on outcome in 
HIV-infected patients.(7) 
 
The basis of our study was to utilise a cost effective modification of the VACS Index 
– the modified VACS index - and find a significant correlation between the predicted 
and actual mortality in a cohort of HIV infected patients who had been initiated on 
anti-retroviral therapy (ART). The index would aid physicians in gauging clinical 
improvement and the effect of other modifiable factors on the health of PLHIV; it also 
gives patients an objective measure of chances of mortality in case of non-compliance 
with treatment and would help in greater adherence to the prescribed ART protocol. 
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2. AIMS 
 
 
 
 
 
 To validate the Modified Veterans Ageing Cohort Study (VACS) Index in a South 
Indian Population infected with the Human Immunodeficiency Virus (HIV) initiated 
on Anti-Retroviral Therapy (ART). 
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3. OBJECTIVES  
 
 
a. To predict patient mortality in HIV infected patients attending the ID 
clinic who have been started on ART regimen under NACO over a 1 
year period from 1
st
 June 2012 to 31
st
 May 2013 and follow up over a 2 
year period from 1
st
 June 2013 to 31
st
 May 2015 using the Modified 
VACS index derived from baseline blood parameters. 
 
b. To compare predicted mortality with actual mortality in the cohort over a 2 year 
period  from 1
st
 June 2013 to 31
st
 May 2015. 
 
c. To use this data to design and implement effective interventions to improve 
outcomes among patients with HIV infection. 
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4.  LITERATURE REVIEW 
 
4.1 STRUCTURE AND CLASSIFICATION 
 
The human immunodeficiency virus (HIV) has been classified in the family of 
retroviruses, which is distinct in the fact that their genetic information happens to be 
encoded by ribonucleic acids (RNA) rather than deoxyribonucleic acids (DNA). They 
act by infecting and consequently destroying CD4 T- cells. HIV is the aetiological 
agent of acquired immunodeficiency syndrome (AIDS).  HIV is classified into 2 
types, both of which are known to cause AIDS: HIV-1, which is the predominant 
cause of the global epidemic; and HIV-2, which is less pathogenic and mostly 
restricted to West Africa. Since the identification of the virus almost three decades 
ago, the pandemic form of HIV-1 has been diagnosed over all continents and 
countries; the infection also encompasses all age groups. Developing countries have 
borne the brunt of HIV/AIDS related morbidity and mortality.(8) 
 
HIV-1 comprises of four distinct lineages, which have been classified into groups M, 
N, O, and P. All four of these groups came into existence secondary to an independent 
cross-species transmission event. Group M was the first to be recognised and is known 
as the pandemic form of HIV-1; it is ubiquitous with regards to its geographic 
distribution. Group O was discovered in 1990 and is much less prevalent than group 
M (<1% of global HIV-1 infections) and is mostly restricted to Cameroon, Gabon, and 
neighbouring countries (Mauclere et al. 1997; Peeters et al. 1997). Group N was 
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identified in 1998 (Simon et al. 1998). It is less prevalent than group O with only 13 
cases having been documented, with all the patients hailing from Cameroon (Vallari et 
al. 2010). Group P was the last to be discovered in 2009; it was detected in a 
Cameroonian woman living in France (Plantier et al. 2009). Despite extensive 
screening, group P has thus far only been identified in one other person, also from 
Cameroon (Vallari et al. 2011). All these groups are known to cause CD4 T-cell 
destruction and AIDS.  
4.2 ROUTES OF TRANSMISSION 
 
HIV-1 is propagated by sexual, percutaneous and perinatal routes; approximately 80% 
of adults get infected following exposure at mucosal surfaces. AIDS usually occurs 
after an approximate duration of 6 to 9 years following infection with the virus. AIDS 
consists of a group of opportunistic infections and other characteristically associated 
conditions, or malignancies. The spectrum of AIDS occurs as a result of the 
underlying immunodeficiency. AIDS occurs as a consequence of chronic HIV 
infection with depletion of CD4 cells. 
 
4.3 ETIOPATHOGENESIS 
 
 HIV targets multiple cell lines such as dendritic cells, macrophages, and CD4+ T 
cells. The most common portal of entry of HIV-1 into a host is through the ano-genital 
mucosa. The envelope protein of the virus, glycoprotein (GP)-120, binds to the CD4 
molecule on dendritic cells. Interstitial dendritic cells in the cervico-vaginal 
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epithelium as well as tonsillar and adenoidal tissue, may also be the  initial target cells 
in infection transmitted via genital-oral sex. Transmission of macrophage tropic rather 
than T-cell tropic viruses are more commonly the cause of newly acquired HIV 
infection. Different co-receptors aid viral entry into cells. GP-120 must bind to the 
chemokine receptor CCR5 as well as CD4 in order for the virus to enter 
macrophages,. Macrophage tropic viruses are designated as R5 in comparison to T cell 
tropic viruses, which are called X4, based upon the CXCR4 receptor on these cells. 
Patients homozygous for a deletion in CCR5 are relatively resistant to R5 infection, 
but cases of X4 infection have rarely been reported in these individuals. 
 
HIV infected cells fuse with CD4+ T cells, leading to spread of the virus. HIV is 
detectable in regional lymph nodes within two days of mucosal exposure and in 
plasma within another three days. Once virus enters the blood, there is widespread 
dissemination to organs such as the brain, spleen, and lymph nodes. The intestinal 
mucosa is also a primary target during initial infection. Preferential destruction occurs 
in CD4+ memory T cells, which may result from direct infection as well as through 
apoptosis. This can lead to an early and disproportionate loss of CD4+ T cells in the 
gastrointestinal compartment, compared to peripheral blood. It has also been proposed 
that microbial translocation, due to changes in the gut mucosal barrier, may be the 
etiology of chronic immune activation in HIV infection. 
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The virus penetrates mucosal epithelium, followed by infection of submucosal CD4+ 
T cells, dendritic cells, and macrophages with subsequent spread to lymph nodes and 
ultimately, plasma. Viremia was documented between 5 to 30 days after experimental 
intravaginal HIV exposure. HIV RNA levels rapidly increase from the earliest 
quantifiable measure to a peak level that usually coincides with seroconversion. 
However, a period of low-level viremia preceding ramp-up viremia, may be more 
common than originally thought. A study of serial samples from patients with 
confirmed early HIV infection was performed to determine if low levels of viremia 
were present in samples that were negative by prior quantitative PCR. On retesting 
with a sensitive qualitative reverse transcriptase PCR assay with sensitivity of 4 copies 
/ mL, 23 of 69 samples were subsequently positive. These specimens preceded the 
first sample with >100 copies / mL by 9-25 days. Whether blood is infectious at this 
low level of concentration is not known. 
 
The HIV DNA level in peripheral blood mononuclear cells provides an estimate of the 
cellular HIV reservoir, which is established soon after infection. In one study of 163 
patients who did not start immediate antiretroviral therapy after diagnosis of acute 
infection, the HIV DNA level and initial CD4 cell count were found to be independent 
predictors of disease progression. 
 
 
 
 
24 
 
4.4 CASE DEFINITION 
  
AIDS occurs as a result of chronic HIV infection and a resultant reduction in the 
number of CD4 cells. A case definition may be stated as a CD4 cell count <200 cells/ 
µL or the presence of any AIDS-defining condition regardless of the CD4 cell count. 
The term advanced HIV infection is often used to refer to infection when the CD4 cell 
count is below 50 cells / µL. AIDS-defining conditions may be defined as 
opportunistic illnesses which occur frequently or more severely secondary to 
immunodeficiency. These include mainly opportunistic infections (Pneumocystis 
jirovecii), malignancies (Kaposi’s sarcoma, lymphoma) & conditions without other 
evident causes, related to uncontrolled HIV infection. Prior to the introduction of 
combination ART, AIDS-associated illnesses were the chief aetiology of morbidity 
and mortality associated with HIV infection.  
 
In the present era of highly active anti-retroviral therapy (HAART), the causes of 
mortality in addition to opportunistic illnesses like tuberculosis, Pneumocystis jiroveci 
pneumonia include adverse events to therapy such as anemia, hepatotoxicity and 
immune reconstitution syndrome. Hence, there is an increased mortality and morbidity 
burden in patients infected with HIV/AIDS secondary to both disease and therapy; the 
requirement for monitoring in patients after initiation of ART is as vital as in ART – 
naïve patients. The median survival of patients with advanced HIV infection (CD4 
cell count <50 cells/microL) is 12 to 18 months in the absence of antiretroviral 
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therapy. Most patients who die of AIDS-related complications have CD4 cell counts 
in this range. 
 
An effective screening programme aids in rapidly identifying people with HIV/AIDS 
and hastens the initiation of antiretroviral therapy (ART); additionally, opportunistic 
infections can be prevented or treated depending on the extent of HIV infection, other 
comorbidities such as haematological abnormalities like leucopenias or anemia can be 
detected and managed appropriately. 
4.5 CLASSIFICATION OF AIDS 
 
AIDS has been classified into 4 clinical stages in accordance with criteria set down by 
the World health Organisation (WHO) with increasing severity from stage I to stage 
IV. The stages are as given under(9) : 
 
 Primary HIV infection – This stage consists of asymptomatic infection or an 
acute retroviral syndrome. An acute retroviral syndrome is usually manifested 
in the form of an acute febrile illness 2-4 weeks after exposure to the virus. It is 
usually accompanied by lymphadenopathy, pharyngitis and skin 
manifestations. Core p24 antigen may be detectable with high blood HIV RNA. 
Blood abnormalities like a profound temporary lymphopenia may be detected. 
Seroconversion from HIV antibody negativity to positivity usually occurs 
during this phase. 
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 Clinical Stage I – It may be either asymptomatic or characterised by persistent 
generalised lymphadenopathy which refers to lymph nodes which are swollen 
to a size > 1 cm in two or more non- contiguous sites, excluding inguinal 
nodes, in the absence of a known cause. 
 
 
 Clinical Stage II – It comprises of patients presenting with moderate (< 10 % 
of presumed or measured body weight) unexplained weight loss. It is also 
characterised by other characteristic infections such as :  
 
a. Recurrent presumed bacterial RTI (two or more in any six-month 
period)  
b. Herpes zoster 
c. Angular cheilitis 
d. Recurrent oral ulcerations occurring twice or more in six months - 
aphthous ulceration, with a halo of inflammation and a yellow-grey 
pseudo-membrane. 
e. Papular pruritic eruptions 
f. Seborrhoeic dermatitis 
g. Fungal paronychia 
 
 Clinical Stage III – This phase is characterised by the following clinical 
features : 
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a. Severe unexplained weight loss (more than 10% of presumed or 
measured body weight). 
b. Unexplained chronic diarrhoea for longer than one month. 
c. Unexplained persistent fever (intermittent or constant and for longer 
than one month). 
d. Oral candidiasis 
e. Oral hairy leucoplakia 
f. Pulmonary TB (current or in last two years) 
g. Severe presumed bacterial infection (e.g. pneumonia, meningitis, 
empyema, pyomyositis, bone or joint infection, bacteraemia ) 
h. Acute necrotizing ulcerative gingivitis or necrotizing ulcerative 
periodontitis. 
i. Unexplained anaemia (< 8 g/dl), neutropenia ( <1000/mm3 ) or 
thrombocytopenia ( < 50000/mm
3 
) for more than one month. 
 
 Clinical Stage IV – This stage is characterised by the following : 
a. HIV wasting syndrome - Unexplained weight loss > 10% of body 
weight accompanied by visible thinning of face, waist and extremities; 
in addition,  either unexplained chronic diarrhoea (lasting > one month) 
or unexplained prolonged or intermittent fever (Documented 
temperature of 37.5 °C or more on occasions with no obvious foci of 
disease, negative blood culture, negative malaria slide and normal or 
unchanged CXR) for one month or more. 
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b. Pneumocystis pneumonia 
c. Recurrent severe or radiological bacterial pneumonia (two or more 
episodes within one year) 
d. Chronic herpes simplex virus (HSV) infection (orolabial, genital or 
anorectal of more than one month, or visceral of any duration) 
e. Oesophageal candidiasis 
f. Extra-pulmonary / Disseminated TB 
g. Kaposi’s sarcoma 
h. CMV (retinitis or CMV infection of an organ other than liver, spleen or 
lymph nodes) 
i. CNS toxoplasmosis 
j. Cryptococcal meningitis or other extrapulmonary Cryptococcus 
infection 
k. HIV encephalopathy 
l. Disseminated non-tuberculous mycobacteria infection 
m. Progressive multifocal leukoencephalopathy 
n. Candidiasis of trachea, bronchi, lungs 
o. Cryptosporidiosis (with diarrhoea lasting more than one month) 
p. Isosporiasis 
q. Any disseminated mycosis (e.g. coccidiomycosis, histoplasmosis, 
penicilliosis) 
r. Recurrent non-typhoidal salmonella septicaemia (two or more episodes 
in last year ) 
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s. Lymphoma (cerebral or B cell non-Hodgkin) 
t. Invasive cervical carcinoma 
u. Visceral leishmaniasis 
 
    
Opportunistic illnesses usually occur when the CD4 cell count falls to levels below 
200 cells/ µL but need not necessarily be so. The half-life of the virus in human serum 
is approximately 1.2 days, about 24 hours in an intracellular milieu, and about 6 hours 
extracellularly. The daily turnover of the virus is equivalent to about 30 % of the total 
body viral burden. But in contrast, only 6 - 7 % of the total CD4 cells turns over each 
day. Hence, AIDS occurs secondary to continuous, high-level replication of HIV, 
causing virus and immune-mediated destruction of CD4 T cells. 
4.6 EPIDEMIOLOGY- GLOBAL 
 
HIV related research has progressed a long way since the first case of HIV was 
diagnosed in 1981 and the subsequent identification of the virus in 1983. (10) 
Azidothymidine (AZT) was the first drug discovered to have therapeutic benefit in 
HIV infection in 1987 followed by the advent of combination retroviral therapy in 
1992.(11)(12) The World Health Organisation (WHO) has recorded 31.8 million [30.1 
million – 33.7 million]  adult patients as infected with the Human Immunodeficiency 
Virus (HIV) with 1.9 million [1.7 million – 2.1 million] people diagnosed for the first 
time, as per the global summary of the AIDS epidemic (2013).(1) As is evident from 
these figures, HIV/AIDS still remains a vital global health issue. 
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4.7 EPIDEMIOLOGY – INDIAN 
 
The first patient in India was identified in 1986 following a serological analysis 
among commercial sex workers in Tamil Nadu in southern India.(13) The National 
AIDS Control Organisation (NACO) statistics reveal that India has the third highest 
number of people infected with HIV in the world. The prevalence has been projected 
to be approximately 20.89 lakh, with 0.27 %  in the adult age group (15-49 years) in 
2011.(2) An overall reduction of 57% in annual new HIV infections among the Indian 
adult population has been documented over the past decade, reflecting the impact of 
the National AIDS Control Programme (NACP) through its interventional measures 
and preventive programmes. (2) 
 
Tamil Nadu is the eleventh largest state in India in terms of area and  the seventh most 
populous state in the country.(14)(15) An estimated 132,590 people (110,563 – 
161,038) people with HIV live in Tamil Nadu with approximately 3148 cases 
diagnosed annually.(16)  
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Table 1 . Estimates of HIV infection from 2007 -2011 in Tamil Nadu(16) 
 
 
 
 
 2007 2008 2009 2010 2011 
Indicator Lower 
Bound 
Estimate Upper 
Bound 
Lower 
Bound 
Estimate Upper 
Bound 
Lower 
Bound 
Estimate Upper 
Bound 
Lower 
Bound 
Estimate Upper 
Bound 
Lower 
Bound 
Estimate Upper 
Bound 
Estimated No. of PLHIV 
Total 1,37,503 1,61,400 1,85,446 1,29,529 1,52,101 1,76,283 1,21,964 1,44,030 1,70,483 1,15,826 1,37,458 1,64,585 1,10,563 1,32,590 1,61,038 
Children 
(<15 yrs) 
5,468 6,940 8,785 5,488 6,959 8,740 5,454 6,922 8,749 5,317 6,761 8,557 5,143 6,504 8,205 
Adults 
(15-49 yrs) 
1,22,415 1,43,101 1,66,153 1,14,350 1,34,027 1,57,143 1,06,794 1,25,940 1,49,605 1,00,006 1,19,180 1,42,664 94,315 1,13,911 1,38,535 
Elderly 
(>49 yrs) 
9,620 11,359 10,508 9,691 11,115 10,398 9,716 11,168 12,129 10,503 11,517 13,364 11,105 12,175 14,298 
Male  1,13,447   1,06,346   1,00,371   95,411   91,705  
Female  47,954   45,666   43,658   42,044   40,885  
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4.8 ANTI-RETROVIRAL THERAPY 
Highly active antiretroviral therapy (HAART) is essential for management of patients 
with HIV infection. The EuroSIDA study compared the early ART period to pre-ART 
and later ART treatment periods, and showed a reduced mortality and progression to 
AIDS on continuous ART. Widespread use of ART has resulted in a marked decline 
in the incidence of most AIDS defining conditions and mortality both in the developed 
and developing world.(3) Suppression of HIV replication is essential to prevent HIV 
associated morbidity and mortality; it also improves the quality of life in patients with 
HIV infection. Strict adherence to antiretroviral therapy is required for adequate 
suppression of HIV infection.(3)  
There are more than 25 antiretroviral medications from six major classes currently 
available for the management of HIV-infected patients. The efficacy of many different 
combination regimens has been studied to determine the optimal approach to 
treatment. Multiple comparative clinical trials have found that combination therapy, 
consisting of two nucleoside reverse transcriptase inhibitor (NRTI) agents plus a third 
active drug from a different class, is most effective in suppressing HIV RNA, 
minimizing drug toxicity, and/or reducing HIV-related morbidity and mortality. 
The major classes of antiretroviral drugs are as given below: 
1. Nucleoside reverse transcriptase inhibitors (NRTIs) 
2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
3. Protease inhibitors (PIs) 
4. Integrase inhibitors (INSTIs) 
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5. Fusion inhibitors (FIs) 
6. Chemokine receptor antagonists (CCR5 antagonists) 
 
The CD4+ cell count thresholds for HAART initiation were recently raised from 350 
to 500 cells / mL in the United States and from 200 to 350 cells / mL in mid- and low-
income countries. Data suggest that these recommendations mean a substantial 
increase in the number of patients who will require treatment and need early HIV 
testing. HAART provides effective treatment options for treatment-naive and 
treatment-experienced patients. Each class targets a different step in the viral life cycle 
as the virus infects a CD4+ T-lymphocyte or other target cell. The use of these agents 
in clinical practice is largely dictated by their ease or complexity of use, side-effect 
profile, efficacy based on clinical evidence, practice guidelines, and clinician 
preference. 
Resistance, adverse effects, pregnancy, and coinfection with hepatitis B virus, or 
hepatitis C virus present important challenges to clinicians when selecting and 
maintaining therapy. 
 
Several toxic syndromes are commonly associated with the use of anti-retrovirals in 
resource-limited settings. Some of the adverse events associated with the use of these 
drugs have been listed below in some detail so as to enable us to understand the risks 
and benefits to be borne in mind prior to initiation of these medications. 
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Hyperlactatemia and lactic acidosis syndrome — Hyperlactatemia causing 
symptoms in PLHIV following the use of anti- retroviral medications, and the lactic 
acidosis syndrome have been linked to chronic use of nucleoside reverse transcriptase 
inhibitors (NRTIs), which can consequently lead on to mitochondrial toxicity. Clinical 
manifestations secondary to a significant increase in serum levels of lactates include 
nausea, vomiting, abdominal bloating, fatigue, weight loss, and hepatomegaly. 
Hyperlactatemia may cause symptoms in patients and elevated lactate levels, while 
lactic acidosis causes severe metabolic derangement as a result of unfavourable 
changes in systemic pH.  
 
Mitochondrial toxicity is a potential risk of long term use of any of the members of the 
NRTI class. The agents which have been detected to be closely associated with lactic 
acidosis include stavudine and didanosine. Zidovudine use has also been found to 
cause lactic acidosis after chronic use . The combination of stavudine and didanosine 
carries a greater risk than either of these agents being used in isolation. Rare cases of 
mitochondrial toxicity have been reported with other agents such as abacavir and the 
nucleotide tenofovir; these agents are not commonly used in resource depleted settings 
due to economic constraints. 
Risk factors for  lactic acidosis as noted in the developed world, include female 
gender, obesity, and stavudine use (17): 
 As per a prospective study conducted in Botswana among 650 ART-naive 
HIV-infected adults initiated on NRTI-containing ART to study patients for 
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ART-associated toxicities, during the study period and after  nearly two years 
of follow-up, 2 % developed moderate symptomatic to severe symptomatic 
hyperlactatemia, which was defined in the study as serum lactate 
>4.4 mmol/L; lactic acidosis (which was defined in the study as symptomatic 
hyperlactatemia in addition to either a pH <7.35 or serum bicarbonate level 
<20 mmol/L) developed in 1 % of the study subjects.(17) 
 
 In another study which was conducted as a retrospective analysis of 1735 
adults (of which 63 % were female subjects) initiated on ART in Soweto 
(South Africa), the  incidence of lactic acidosis was found to be similar (~ 1.3 
%). (18) 
The incidence of lactic acidosis in resource-limited settings has been observed to be 
higher than the 0.1 - 0.4 % as described in studies which were conducted in resource-
rich settings, and may be considered a reflection of the frequent use of stavudine in 
resource depleted regions. Mortality rates from different studies have varied from 7 to 
30 percent; patients with a lower body weight (<45 kg) and higher levels of lactate 
have been noted to have increased rates of mortality in one study.(19) 
 
Serum lactate and pH determination are the diagnostic tests that are performed in 
patients with suspected lactic acidosis syndrome in resource-rich settings. In areas 
which have limited laboratory facilities, the anion gap may be simply calculated from 
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serum sodium, bicarbonate and chloride.(17) In areas where laboratory monitoring are 
not easily available, clinical suspicion of lactic acidosis (eg, symptoms of nausea, 
vomiting, abdominal discomfort, weight loss, fatigue) should prompt immediate 
discontinuation of antiretroviral therapy. An increased anion gap would be evidence in 
support of lactic acidosis syndrome. 
 
As per a study conducted among 56 patients with mitochondrial toxicity which was 
associated with stavudine use, switching to zidovudine-containing ART was found to 
be safe.(18) Since antiretroviral medication selection is mainly limited to older NRTIs 
in many resource depleted areas, data of this nature may be helpful in drug selection.  
\ 
Pancreatitis — Dideoxynucleoside analogues (didanosine and stavudine) are the 
antiretroviral agents which have been most closely associated with pancreatitis.(20) 
Differential diagnoses for antiretroviral-induced pancreatitis are pancreatitis 
secondary to other etiologies such as alcohol use, hyperlipidemia, and cholelithiasis; 
antiretroviral-induced pancreatitis may be aggravated by other causes such as those 
mentioned above. Clinical features of pancreatitis include severe abdominal pain 
radiating to the back, nausea and vomiting. Severe pancreatitis can be fatal, especially 
if associated with a lactic acidosis syndrome.(17) 
 
In resource-deficient settings, the net rate of confirmed pancreatitis is comparatively 
low in studies, although the limited availability of diagnostic tests may affect the 
37 
 
ability to diagnose this complication. 1029 patients with advanced AIDS in a home-
based care program in rural Uganda were followed for clinical signs of antiretroviral 
toxicity without any facility for laboratory monitoring.(21) Despite almost all patients 
being initiated on stavudine-containing ART, only 0.3 percent received a clinical 
diagnosis of pancreatitis following a total of 11,268 patient-months of observation. In 
stark contrast, a retrospective study that was conducted in a resource-rich setting 
detected that the incidence rate for clinical and/or chemical pancreatitis in patients 
who were receiving stavudine-containing regimens ranged from 0.77 - 1.84 per 100 
person-years, which was considerably higher than in the Uganda study.(20) 
 
The combination of low body weight and the didanosine use may cause a resultant 
increase in  the risk of pancreatitis. In a retrospective review of 575 patients who had 
been treated with tenofovir and didanosine (this is a combination that is no longer 
recommended), didanosine alone, or tenofovir alone, all 6 cases of pancreatitis were 
reported in patients who were female, weighed < 60 kg and received didanosine, 
either alone (n = 1) or in addition to  tenofovir (n = 5).(22) 
 
Peripheral neuropathy — Stavudine and didanosine are antiretroviral agents that are 
most frequently associated with peripheral neuropathy closely followed 
by nevirapine.(23) Other causes of peripheral neuropathy include advanced HIV 
infection itself, aging, diabetes, and nutritional deficiencies. Concomitant use 
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of isoniazid or other neurotoxic medications may further increase the risk of 
peripheral neuropathy.  
 
Unlike the relatively low percentage of patients who develop lactic acidosis or 
pancreatitis while receiving these agents, peripheral neuropathy occurs in a high 
percentage of patients, both in resource-rich and resource-poor countries(24): 
 In a Kenyan cohort of 1286 patients followed for nearly two years on ART 
(generally stavudine, lamivudine, and nevirapine), 54 percent switched ART 
regimens; 21 percent of these patients switched because of symptoms of 
peripheral neuropathy.(25) 
 In a small study of 102 treatment-naive HIV-infected Ugandan patients and 25 
HIV-seronegative controls, 54 percent of the treated patients reported foot 
numbness after six months of stavudine-containing ART, including 38 percent 
of those with no symptoms at baseline.(26) 
 In a cohort of 199 HIV-infected Kenyans, women were almost 10 times more 
likely to develop peripheral neuropathy than men during one year of follow-up, 
after controlling for other factors, such as CD4 cell count, body mass index, 
ART regimen, and tuberculosis treatment.(27) 
Despite concerns about stavudine-induced neuropathy, the mortality benefits of ART 
outweigh potential neurologic morbidity when no medication alternatives exist. As 
noted above, in an effort to reduce adverse effects, the WHO has reduced the 
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recommended starting dose of stavudine in adults to 30 mg twice a day regardless of 
body weight.(28) 
 
In patients who develop this complication, replacement of stavudine with less toxic 
agents, such as tenofovir, is suggested when feasible, since switch strategies to 
alternative agents have been associated with improvements in mitochondrial DNA 
content and mitochondrial morphology in resource-rich settings.(29) 
Central nervous system effects — Efavirenz may commonly cause acute subjective 
neurologic symptoms, typically of limited duration, which can impact adherence. 
The overall frequency of this complication appears to differ by racial group and may 
be related to genetic influences on drug metabolism. The cytochrome (CYP)2B6 
516G>T polymorphism (referred to as the "T/T genotype") 
impairs efavirenz metabolism and occurs more commonly in Africans than in 
Caucasians. For example, in one study, the T/T genotype was reported in 3 percent of 
European-Americans compared with 20 percent of African-Americans.(30) In another 
study of 142 HIV-infected patients from South Africa, the prevalence of this genotype 
was 13 percent.(31) 
 
The higher prevalence of the T/T genotype among Africans may explain, in part, 
reports of increased CNS toxicities such as depression, anxiety, and severe sleep 
disturbance in Africans, since increased symptoms have been directly related to higher 
serum drug concentrations. If CNS symptoms continue after the first month of 
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treatment, consideration should be given to an alternative therapy, such as 
a nevirapine. 
 
Central nervous system effects may also be exacerbated if the standard dose 
of efavirenz (600 mg) is increased to 800 mg daily, as is sometimes done to counter 
pharmacologic interactions between efavirenz and rifampin in TB-coinfected patients. 
However, this dosing strategy has been linked to increased toxicity in patient subsets 
with the T/T genotype. If a patient develops significant CNS side effects on efavirenz 
at the 800 mg dose, consideration should be given to dose reduction, particularly if 
viral suppression has already been attained.  
 
Anemia — Since zidovudine frequently causes anemia, monitoring of hemoglobin is 
advisable. Anemia generally occurs during the first six months of zidovudine therapy 
and may be completely asymptomatic (with only macrocytosis as a marker of 
zidovudine use) or symptomatic with fatigue or dyspnea. In severe cases, zidovudine-
induced anemia can present with life-threatening aplastic crisis. 
 
In a study of 3312 treatment-naive patients in Uganda and Zimbabwe, 219 (6.6 
percent) on zidovudine-containing regimens exhibited severe anemia (hemoglobin 
<6.5g/dL) by week 48. This rate is higher than that seen in industrialized nations, and 
may reflect lower baseline hemoglobin levels secondary to other concomitant 
infections (such as hookworm or tuberculosis). Women and those with lower baseline 
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hemoglobin, CD4 cell counts, and body mass index at baseline were at significantly 
higher risk of developing severe anemia. Reassuringly, the use of cotrimoxazole was 
not a risk factor for this adverse event. 
 
Where laboratory capabilities allow, assessment for other causes of anemia may also 
be warranted, such as iron deficiency, medication-induced hemolysis (eg, dapsone), or 
gastrointestinal bleeding. Parvovirus B19 infection, another potential cause of anemia 
in HIV-infected patients, has been rarely implicated in resource-limited settings, but 
this may be related to diagnostic limitations. A study in Brazil found parvovirus B19 
IgG seropositivity in 62.8 percent of 261 consecutive HIV-infected patients, and 
suggested that seronegative patients may be at risk of infection during epidemic 
periods. If bone marrow infiltration (eg, by lymphoma or Mycobacterium avium 
complex), or suppression is suspected (eg, medications), a bone marrow biopsy may 
be indicated, where feasible. 
 
Zidovudine use may be even more problematic in areas with high prevalence of 
certain parasitic coinfections that can exacerbate anemia, such as malaria or 
hookworm. Tuberculosis may overshadow parasites as a major contributor to anemia 
in populations with a high prevalence of HIV/TB coinfection. In this situation, 
treatment of tuberculosis may lead to overall improvement of anemia. Since a patient 
with baseline anemia is at higher risk for increasing severity of anemia after initiation 
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of zidovudine, baseline testing with a spun hematocrit would be helpful if laboratory 
testing is limited. 
 
Lipodystrophy — With the introduction of effective antiretroviral therapy, 
descriptions of patients with body shape abnormalities, such as central fat 
accumulation and peripheral fat loss emerged. The term "HIV-associated 
lipodystrophy syndrome" was coined, but it soon became clear that some patients have 
pure lipoatrophy, others have fat accumulation, and a subset of patients have a mixed 
picture of both morphologic features. Lipodystrophy can also be associated with 
disorders in glucose and lipid metabolism.  
 
In settings where discrimination is still entrenched, stigmatizing physical features 
(such as malar atrophy) may be particularly detrimental to adherence and patients' 
well-being. Risk factors for lipoatrophy include use of stavudine or didanosine, and to 
a lesser extent, zidovudine. 
 
The frequency of lipodystrophy in resource-limited settings is substantial, which 
likely reflects the widespread use of medications, such as stavudine, which are prone 
to cause metabolic and body shape changes, such as lipoatrophy. Two studies from 
Africa demonstrated prevalence rates ranging from 30 to 70 percent; stavudine was a 
significant predictor of risk. 
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Data from developed countries suggest that use of protease inhibitors (PIs) may be a 
significant factor in lipodeposition; however, there is limited information on the role 
of PIs in lipodystrophy syndromes in resource-limited settings at this time because 
this class of antiretrovirals is infrequently prescribed. 
 
Treatment for lipoatrophy is essentially limited to discontinuation of the offending 
agent; however, clinical improvement is exceedingly slow and full recovery may not 
necessarily occur. 
 
Hepatotoxicity — All antiretroviral agents can cause hepatotoxicity, although 
different drugs vary in their propensity to cause liver damage. Of the 
NRTIs, stavudine and didanosine are the most likely to cause hepatotoxicity, probably 
because of the mitochondrial effects of these agents. Full-dose ritonavir is the most 
hepatotoxic of the PIs, but this drug is rarely used at such doses anymore; when used 
as a low-dose pharmacologic booster of other agents, ritonavir is less commonly 
associated with liver injury. Of the non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), nevirapine is more likely to cause hepatotoxicity than efavirenz in patients 
with detectable viremia. However, in resource-rich settings, nevirapine appears to be 
relatively safe in patients with viral suppression who are switched to this agent. 
 
The risk of nevirapine hepatotoxicity is concentrated in certain risk groups. In a 
prospective cohort study of 146 pregnant females in Mozambique, severe 
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hepatotoxicity was more common in those with CD4 cell count 
>250 cells/mm3 compared with patients whose CD4 cell count was 
<250 cells/mm3 (6 percent versus 0 percent). Having a CD4 count 
>400 cells/mm3 has been identified as a risk factor for nevirapine hepatotoxicity in 
men; at this time, this finding is less relevant in resource-limited settings because such 
patients rarely meet current WHO or national guidelines for ART initiation.  
 
Coinfection with viral hepatitis also increases the likelihood of ART-induced 
hepatotoxicity. For example, in a Nigerian study of 1564 patients, the risk for serious 
hepatotoxicity 24 weeks after initiation of ART was 3.1 percent in patients coinfected 
with HBV compared with only 0.5 percent in patients with HIV alone; hepatotoxicity 
was not associated with either baseline HBV DNA concentration or HBeAg status. 
Coinfection with hepatitis C is an important risk factor as well, but this diagnosis 
tends to be more common in resource-rich areas. 
 
Other risk factors for ART-related liver injury include concomitant use of other 
hepatotoxic drugs (such as antituberculous agents or herbal remedies) and the 
presence of abnormalities of aminotransferases at baseline. 
Hypersensitivity reactions — Though virtually any drug can cause a hypersensitivity 
syndrome, nevirapine and abacavir are associated with uncommon but well-
documented life-threatening reactions. Prior to starting patients on these medications, 
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the clinician should discuss potential symptoms that would alert the patient to the 
possibility of this reaction.  
 
Common concomitant medications such as antituberculous 
medications, trimethoprim-sulfamethoxazole (TMP-SMX), beta-lactam antibiotics, 
and herbal remedies may provoke hypersensitivity reactions (HSR) as well. Thus, it is 
important to consider all medications as potential causes. 
 
Nevirapine — This agent accounts for over three-fourths of NNRTI prescriptions in 
resource-limited settings.(32) Hypersensitivity reactions (HSR) may present with rash, 
fever, hepatitis, or eosinophilia, usually during the first 16 weeks of therapy. In a 
Ugandan cohort of 1029 patients studied during a 19-month period, the incidence of 
nevirapine HSR was 1.7 percent, including one death.(21) Rechallenge with 
nevirapine is contraindicated after an HSR.  
 
Nevirapine HSR is more common in women with CD4 cell count <250 cells/mm3 and 
men with CD4 cell count <400 cells/mm3. The risk of nevirapine HSR is related to 
the pretreatment CD4 cell count and the presence of HIV viremia. Thus, if the 
patient's CD4 count rises to >250 cells / mm
3
 on treatment, nevirapine does not need 
to be discontinued. Also, the risk of hypersensitivity reaction is mitigated when viral 
suppression has already been achieved. Thus, switching a patient to nevirapine due to 
an adverse event related to another drug is much less likely to lead to HSR if viral 
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suppression has already been achieved.(33) Lead-in dosing (eg, 200 mg daily for 14 
days followed by twice-daily dosing) is recommended to decrease the risk of adverse 
events.  
 
Abacavir — The presence of the HLA-B*5701 allele greatly increases the risk 
of abacavir HSR, and its absence markedly reduces the risk of an immunologic 
reaction.  
Testing for HLA-B*5701 has become the standard of care in many developed 
countries, but is rarely available in resource-limited settings. Fortunately, this 
haplotype is rare in Africans; thus, it appears abacavir can be used relatively safely in 
this population with close monitoring. Of 599 Ugandan patients, only 2 percent of 
those randomly assigned to abacavir experienced an HSR compared with 4.7 percent 
who were treated with nevirapine.(34) 
 
Nephrotoxicity — There is concern that the prevalence of nephrotoxicity may 
increase as the nucleotide reverse transcriptase inhibitor, tenofovir, becomes more 
widely available in Sub-Saharan Africa. Tenofovir use has been associated with renal 
insufficiency, particularly in patients with preexisting diabetes or hypertension. 
 
However, in an observational study of 3316 treatment-naive patients in Zimbabwe and 
Uganda, despite high prevalence of baseline mild to moderate renal insufficiency and 
common use of tenofovir (74 percent), severe renal dysfunction after 96 weeks was 
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rare, and tenofovir-free regimens offered only marginal benefit in improving baseline 
glomerular filtration rate.(35) This finding is particularly reassuring since prior to 
treatment, 45 and 7 percent of the patient population had mild or moderate renal 
insufficiency, respectively. 
Tenofovir also has dual activity against hepatitis B and is often prescribed to patients 
with HBV coinfection in several countries, including South Africa and Nigeria. 
 
Myopathy — In rare cases, diffuse muscle fatigue or weakness, generally of insidious 
onset, can result from treatment with zidovudine. Patients must be monitored for 
zidovudine-related myopathy through careful history and physical examination. If 
laboratory monitoring is available, a creatine kinase should also be checked in 
suspected cases; when elevated, a muscle biopsy may be considered. Zidovudine 
should be discontinued if this diagnosis is suspected.  
 
Rash — Skin eruptions are a common complication of NNRTIs, such 
as efavirenz and nevirapine. A case-control study was performed among Thai patients 
who developed rash after starting nevirapine-containing ART compared with patients 
who did not.(36) Risk factors for the development of rash included a prior history of 
drug allergy and low body weight; risk was also elevated with higher CD4 cell counts 
(odds ratio, 1.2 per each 50 cells/mm3 increment). 
If a rash occurs, it is generally safe to continue therapy 
with nevirapine or efavirenz with close monitoring of the patient. However, it is 
48 
 
crucial to distinguish self-limited mild drug rash from life-threatening, systemic 
reactions, such as Stevens-Johnson Syndrome (SJS) or hypersensitivity reaction 
(HSR), which have both been described in association with nevirapine 
and abacavir.(37) Rash that is associated with mucosal involvement (eyes, mouth) 
suggests SJS, while constitutional symptoms, fever, and eosinophilia suggest HSR.  
 
Consideration should also be given to other potential etiologies of rash, such as 
medications, concomitant infections (eg, secondary syphilis) or worsening of 
eczematous rashes or eosinophilic folliculitis during ART-associated immune 
reconstitution.  
 
Gastrointestinal complications — Protease inhibitors often cause diarrhoea, which 
may or may not be self-limited. If the diarrhoea persists, opportunistic infections (eg, 
Mycobacterium avium intracellulare) should be excluded, especially in patients with 
advanced immunosuppression.  
 
Dyslipidemia and metabolic complications — Abnormal fasting lipid profiles and 
impaired glucose tolerance are common among patients on ART.(38) In the NRTI 
class, stavudine and zidovudine are more likely to be associated with dyslipidemia 
than abacavir or tenofovir. Amongst the NNRTIs, efavirenz is more likely to cause 
dyslipidemia than nevirapine, which is associated with favorable increases in HDL-c. 
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Lipid profiles were monitored at 12 and 24 months after the initiation of ART in 374 
patients in Uganda, the vast majority of whom were taking stavudine, lamivudine, and 
nevirapine.(39) After 24 months, increases in HDL-cholesterol levels were substantial 
and proportionally greater than increases in total cholesterol or LDL-c levels, which 
were likely related to nevirapine. 
Cardiovascular events — Cardiovascular disease is prevalent in many resource-
limited settings and traditional cardiac risk factors may be on the rise. According to 
statistics from the WHO, cardiovascular deaths (including coronary artery disease and 
cerebrovascular disease) comprise 15 percent of all deaths in low-income countries, 
substantially greater than the 5.7 percent of deaths from HIV/AIDS.(40) A survey 
performed among persons living in rural and urban communities in South Africa 
assessed the influence of urbanization on nutritional status and overall health.(41) This 
study documented that those living in urban settings had elevated levels of LDL-c and 
total cholesterol, higher rates of obesity, and significantly higher proportions of 
persons with elevated systolic blood pressure than those living in rural areas. 
 
Abacavir and didanosine have been associated with an increased likelihood of 
myocardial infarction in some studies in resource-rich settings, though these 
associations remain controversial and the underlying mechanisms have not been 
conclusively elucidated.(42) Further research is needed to define the impact of 
antiretroviral medications on cardiovascular disease in low-income nations 
undergoing lifestyle changes as a result of industrialization. 
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Special considerations during pregnancy — Females of childbearing potential are 
disproportionately affected by HIV infection in resource-limited settings. Pregnancy is 
common because many infected men and women remain sexually active in the 
absence of effective contraception and there are strong social pressures to 
procreate.(43) The teratogenic potential of certain antiretroviral medications and the 
use of nevirapine in pregnancy for maternal health or prevention of mother-to-child 
transmission are reviewed elsewhere. Due to neural tube defects observed in monkey 
studies and a few clinical cases observed in humans, efavirenz is classified as a 
Pregnancy Category D drug and is best avoided in women who are planning to or may 
become pregnant. 
 
4.9 IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME 
 
"Immune reconstitution inflammatory syndrome" (IRIS) describes a collection of 
inflammatory disorders associated with paradoxical worsening of pre-existing 
infectious processes following the initiation of highly active antiretroviral therapy 
(HAART) in HIV-infected individuals.(44) Pre-existing infections in individuals with 
IRIS may have been previously diagnosed and treated or they may be subclinical and 
later unmasked by the host's regained capacity to mount an inflammatory 
response.(45) 
If immune function improves rapidly following the commencement of HAART, 
systemic or local inflammatory reactions may occur at the site or sites of the 
preexisting infection. This inflammatory reaction is usually self-limited, especially if 
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the preexisting infection is effectively treated. However, long-term sequelae and fatal 
outcomes may rarely occur, particularly when neurologic structures are involved. 
It is generally accepted that the diagnosis of IRIS requires the worsening of a 
recognized ("paradoxical" IRIS) or unrecognized pre-existing infection ("unmasking" 
IRIS) in the setting of improving immunologic function. Most or all of the following 
features should be present in order to make the diagnosis: 
●The presence of AIDS with a low pretreatment CD4 count (often less than 
100 cells/microL). One important exception to this general rule is tuberculosis. 
IRIS secondary to pre-existing M. tuberculosis infection may occur in individuals 
with CD4 counts >200. 
●A positive virologic and immunological response to ART. 
●The absence of evidence of drug-resistant infection, bacterial superinfection, 
drug allergy or other adverse drug reactions, patient noncompliance, or reduced 
drug levels due to drug-drug interactions or malabsorption after appropriate 
evaluation for the clinical presentation. 
●The presence of clinical manifestations consistent with an inflammatory 
condition 
●A temporal association between HAART initiation and the onset of clinical 
features of illness 
One prospective study found that patients developed IRIS within a median of 48 days 
(29 to 99 days).(46) 
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When a diagnosis of IRIS is considered highly likely, further or repeated invasive 
diagnostic procedures to locate an occult infection may be reasonably delayed, 
deferred, or altogether avoided. However, localized drainage (with appropriate 
cultures) is indicated for symptomatic relief of mycobacterial lymphadenitis as well as 
for diagnostic purposes. 
 
4.10 NATIONAL AIDS CONTROL PROGRAMME 
 
ART has been dispensed free of cost under the National AIDS Control Programme 
(NACP II) since April 2004. More than 300 ART centres are functional in India at 
present and more than 516,000 patients are receiving ART at these centres. 
Approximately 30,000 patients receive free ART in the private sector.(4) 
Consequently, there has been a progressive decline in annual AIDS related mortality 
with an estimated 1.5 lakh lives being saved due to ART till 2011.(2) The number of 
ART centres is gradually being scaled up in a phased manner. 
4.11 MORTALITY IN HIV / AIDS 
 
In most patients infected with HIV on adequate treatment with antiretroviral therapy 
(ART),  
the incidence of AIDS-defining events  is very low, with often undetectable HIV-
RNA levels on available assays. Despite adequate treatment with ART, excess 
mortality has been observed in these individuals as compared to matched controls and 
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is not explained by parameters like CD4 count alone. Studies like the SMART trial 
point towards probable  etiologies such as  HIV-associated inflammation with 
increased risk of hypercoagulability and aging-associated organ system injury.(5) In 
this trial, HIV-infected persons were randomized to continuous ART or therapy 
guided by CD4 T cell counts. Subjects randomized to interrupted therapy had a higher 
risk of morbidity and mortality than subjects on continuous therapy. Interruption of 
ART regimens resulted in a rapid rise in inflammation and coagulation related 
biomarkers which correlated with an increased risk of death, AIDS, and 
cardiovascular disease (CVD). The mechanisms which link HIV replication to 
inflammation, coagulopathy, and disease progression remain largely undefined.(47) 
There has been an increasing body of evidence suggesting that the risk of serious non-
AIDS conditions like cardiovascular disease (CVD), renal or hepatic disease and non-
AIDS defining malignancies is increased in people with HIV infection as compared to 
matched controls.(6) Multiple trials have been conducted to assess correlation of non-
traditional with traditional markers of inflammation to monitor patients with 
potentially modifiable risk factors. 
 
4.12 NEED FOR PROGNOSTIC INDEX 
 
Physicians treating patients with HIV infection are frequently asked for prognostic 
assessments and quality of life after initiating therapy. Prognostic systems such as risk 
factors, staging systems, statistical models, and computer algorithms have been 
developed to standardize and enhance the accuracy of prognostic assessments. 
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Although diverse techniques are used to develop these systems, all use a sample of 
patients for whom the outcome is known to relate baseline characteristics to an 
outcome of interest. Once a system is developed, it can be used to generate predictions 
for patients whose outcome is not yet known. A common problem in the application 
of prognostic systems is that the accuracy of the predictions degrades from the sample 
in which the system was first developed to subsequent application; that is, the systems 
do not generalize .(48) 
4.13 THE VETERANS AGING COHORT STUDY (VACS) INDEX 
 
The Veterans Aging Cohort Study (VACS) is a longitudinal, prospective multi-site 
observational study of HIV infected and uninfected patients evaluated in Veterans 
Administration Medical Centre (VAMC) infectious disease and general medical 
clinics.(49) The Veterans Aging Cohort Study (VACS) Risk Index was designed to 
predict mortality in HIV patients who have been treated for one year, using a simple 
scoring system. It was intended  to take into account all possible interactions of HIV 
disease, comorbidities, substance abuse, and adverse drug reactions secondary to 
treatment, on outcome in HIV-infected patients.(7) As most patients would be on ART 
for extended periods, an on-treatment index was considered to be more relevant to 
health professionals and HIV positive people, for evaluating prognosis after initiation 
of therapy. There was also a possibility of an alteration in reported relationships 
between known biomarkers and mortality subsequent to initiation of treatment. (5) 
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It was developed in HIV-infected US veterans and validated in independent cohorts 
from the US and Europe participating in the Antiretroviral Therapy Cohort 
Collaboration (ART-CC).(5) Prognostic indices were developed using data from a 
cohort of more than 33,000 HIV-infected veterans for whom data on inpatient and 
outpatient diagnoses, laboratory results, and pharmacy dispensations were 
documented during routine clinical visits starting from the initial visit. VACS 
included all HIV-infected Veterans in Veterans Administration (VA) care. 
Development and validation datasets were combined to evaluate index performance 
within important patient subgroups [women, those with HIV-1 RNA<500 copies/ml, 
and Hepatitis C (HCV) co-infected patients]. (5) 
 
The VACS index comprised of the following prognostic factors – age of the 
individual in years, CD4 count, HIV-1 RNA,  haemoglobin, aspartate transaminase 
(AST) & alanine transaminase (ALT) levels, platelets, creatinine and HCV status.  
 
Two composite markers of hepatic injury (FIB-4) and renal injury (eGFR) were 
derived from the constituent parameters of the VACS index. FIB-4 has been validated 
as an indicator of liver fibrosis and is calculated using age, AST, ALT & platelets. 
Using a lower cutoff value of 1.45, a FIB-4 score <1.45 had a negative predictive 
value of 90% for advanced fibrosis (Ishak fibrosis score 4-6 which includes early 
bridging fibrosis to cirrhosis). In contrast, a FIB-4 >3.25 would have a 97% specificity 
and a positive predictive value of 65% for advanced fibrosis. In the patient cohort in 
which this formula was first validated, at least 70% patients had values <1.45 or 
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>3.25. Authors argued that these individuals could potentially have avoided liver 
biopsy with an overall accuracy of 86 %. 
 
FIB-4 ={age(in years) x AST}/(platelets in 100/L x √ ALT) 
 
The estimated glomerular filtration rate (eGFR) is calculated using the Modification 
of Diet in Renal Disease (MDRD) equation as given under: 
 
eGFR =186.3 x (creatinine)
-1.154 
x (age)
-0.203 
x (0.742 for women) x (1.21 if 
Black). 
 
This equation has been validated as a marker of impaired renal function.  
 
The HCV infection status was derived from a documented diagnosis based on a 
positive antibody test or detectable plasma HCV-RNA in the patient’s medical 
records. The patients were assumed to remain either positive or negative after being 
tested once.  
 
During the initial days of the study, in the time period between 1
st
 January 1997 and 
1
st
 August 2002, the original VACS index consisted of, in addition to the components 
already mentioned above, AIDS-defining conditions, hepatitis B serology and 
substance abuse or dependence (alcohol or drugs).(50) As AIDS events were 
uncommon among those on ART and had a variable association with mortality and  
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also, the diagnoses of substance abuse and hepatitis B infection were inconsistently 
measured across cohorts, the index was narrowed down to the present 
components.(51)(52) 
 
The VACS index was compared with a Restricted Index that included only age and 
conventional HIV risk factors (CD4 count and HIV-1 RNA) in the same cohort. Each 
prognostic factor was categorized into levels for convenience in future application in 
clinical settings. The number of categories of CD4 count, HIV-1 RNA, anaemia and 
renal function were expanded compared with previous analyses. The score can be 
used to estimate risk of all-cause mortality using a conversion factor. The individual 
clinical parameters were considered as categorical measures; the score was weighted 
to indicate an increasing risk of all-cause mortality with increasing score. 
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Table 2.Components of the VACS Index 
 
  Points 
Age (years) < 50 
50-64 
≥65 
0 
12 
27 
CD4-cell count, cells/mm3 ≥500 
350-499 
200-349 
100-199 
50-99 
<50 
0 
6 
6 
10 
28 
29 
HIV-1 RNA, copies/ml <500 
500-1X105 
≥ 1X105 
 
0 
7 
14 
Haemoglobin, g/dl ≥14.0 
12.0-13.9 
10.0-11.9 
<10 
0 
10 
22 
38 
FIB-4 <1.45 
1.45-3.25 
>3.25 
0 
6 
25 
eGFR, ml/min ≥60 
45.0-59.9 
30.0-44.9 
<30 
0 
6 
8 
26 
Hepatitis C infection  5 
 
 
FIB 4 : (years of age x AST)/(platelets in 10
9/L x √ ALT). eGFR : 186.3 x 
(creatinine)
-0.154  
x (age)
-0.203 
x (0.742 for women) x (1.21 if Black) ALT. alanine 
transaminase; AST, aspartate transaminase; cART, combination antiretroviral therapy; 
eGFR, estimated Glomerular Filtration Rate; FIB - Fibrosis Index; IQR-inter-quartile 
range. Hepatitis C diagnosis, positive antibody test or detectable virus. (53)(5) 
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The Christian Medical College (CMC) Vellore has been involved in HIV care and 
training right from the onset of the HIV epidemic in India in 1986. Medicine Unit I 
and Infectious Diseases currently take care of over 44,118 outpatients and 2217 
inpatients annually. Interdisciplinary Infectious Disease (ID) Clinic involving 
Medicine, Paediatrics, Dermatology and STD and Social Work provides 
comprehensive care to about 3873 HIV patients every year. The department also 
conducts support group meetings for HIV positive people to provide social support to 
the patient and their families as well as provides income generation assistance. The 
Obstetrics and Gynaecology department of the hospital runs Prevention of Parent to 
Child Transmission (PPTCT) which provides counselling for couples who visit the 
antenatal clinic. Interventions to reduce vertical transmission of HIV are provided to 
HIV positive mothers. Free ART drugs are provided to HIV infected people through 
ACTFID (ACC-CMC Trust for Infectious Diseases) and with assistance of 
NACO.(54) 
 
In view of the probability of increased mortality despite being compliant with the best 
available ART, the need for a reliable prognostic indicator was felt. The target 
population treated by the ID clinic and receiving ART from the NACO - ART centre 
was different in terms of their epidemiological characteristics from the constituent 
population of the VACS cohort. Patients from both the paediatric and adult age group 
come under the purview of the ART centre.  
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The VACS Index integrates nine component parameters into a single score which aids 
in reflecting the disease burden of the patient. A composite index such as the VACS 
index has a few  major advantages as compared to individual biomarkers. First, a 
score gives the clinician an overall sense of the patient’s condition and can be used to 
predict the progress of the patient’s clinical condition including increased or decreased 
risk of morbidity or mortality. While prognosis could also be obtained by entering 
individual values into a risk calculator, the simplicity of a single number is appealing 
for ease of interpretation by both clinician and patient. Second, thresholds for concern 
of these routinely monitored measurements have typically been more extreme than 
those identified by the index. The exercise of calculating the integrated impact of 
several biomarkers can help clinicians recognize the importance of more moderate 
abnormalities that may still be associated with disease.(5) 
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5. METHODS 
5.1 SETTING 
 
The Christian Medical College, Vellore, is a 2000 bedded, tertiary care centre in South 
India. The Department of Medicine Unit-I and Infectious disease has been providing 
care to PLHIV from the beginning of the HIV epidemic in India in 1986. An 
interdisciplinary infectious disease clinic runs on Wednesday afternoon and two full 
OPD days on Tuesday and Friday, involving medicine, pediatrics, dermatology and 
venereology and social work which provides comprehensive care to PLHIV.  
 
Patients were recruited from referrals to the NACO – ART centre from the Infectious 
Diseases (ID) clinic. The ART centre in the Christian Medical College Vellore was 
inaugurated in 2008 and has an annual turnover of approximately 4000 HIV patients 
every year. The ID clinic evaluates patients of all age groups diagnosed with HIV 
infection/AIDS, predominantly from the South Indian states of Tamil Nadu, Andhra 
Pradesh and Karnataka, with an interdisciplinary team from Medicine, Paediatrics and 
Dermatology.  
5.2 STUDY DESIGN 
 
Our study recruited subjects by retrospective analysis from old electronic medical 
records into a cohort from the time period 1st June 2012 to 31st May 2013.  
The duration of follow up of the patients was two years beginning from 1
st
 June 
2013 and ending on 31
st
 May 2015. 
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The sample size was calculated using the assumptions made below: 
 n = Z * p * q  
           d
2 
 
Z = Standardized normal deviate 
p = proportion / prevalence of mortality in population of interest 
q = 100 – p 
d = Clinically expected variation 
 
For the year 2012 –2013, the total population of PLHIV started on first line NACO – 
ART was 353 with an outcome of mortality in 31. 
 
Prevalence of mortality (p) = 31/353 = 8.8 % 
 
Anticipating a clinical variation (d) of 3.5%,  and a Z – value for a 95 % confidence 
interval corresponding to 1.96, 
 
 n = ( 1.96 )2 x 8.8 x 91.2   =   252 
                       (3.5)
2 
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5.3 INCLUSION CRITERIA  
 PLHIV started on first line NACO ART regimen from ID clinic in CMC 
Vellore during the period from 1st June 2012 to 31st May 2013.  
 
5.4 EXCLUSION CRITERIA 
 
 PLHIV started on ART before or after the specified period (1st June 2012 – 31st  
May 2013).  
 PLHIV started on non-NACO ART.  
 
5.5 VARIABLES 
 
After recruitment, baseline blood investigations with other patient related information 
such as age and gender were used to complete the clinical research form. The data 
filled in the proforma included the following variables: 
 
 Age  
o < 50 years 
o 50 - 64 years 
o ≥ 65 years 
 
 Gender  
o Male 
64 
 
o Female 
 
 CD – 4 count 
 
o >500 /mm3 
o 350 – 499 /mm3 
o 200 – 349 /mm3 
o 100 – 199 /mm3 
o 50 – 99 /mm3 
o < 50 /mm3 
 
 Haemoglobin  
 
o > 14 g / dl  
o 12 – 13.9 g / dl  
o 10 – 11.9 g / dl  
o < 10 g / dl  
 
 AST                      
 ALT  
 Platelets  
 Creatinine  →  eGFR  
 Hepatitis C infection  
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The AST, ALT and Platelets count were used to derive a composite variable called the 
FIB-4. The formula for calculation of the FIB-4 index is as given below: 
 
FIB-4 = {Age (in years) x AST}/(Platelets in 100/L x √ ALT) 
 
Details with regard to the validity of the FIB-4 index have already been elucidated in 
detail in the literature review. 
 
The creatinine, age and gender were used to derive the estimated glomerular filtration 
rate by using the Modification of Diet in Renal Disease (MDRD) formula as given 
below: 
 
eGFR =186.3 x (creatinine)
-1.154 
x (age)
-0.203 
x (0.742 for women) x (1.21 if 
Black). 
 
The HIV – RNA titres were not considered in the Modified VACS Index as it was not 
feasible to be done on a routine basis for most patients due to the lower socio 
economic status of the average patient attending the ID clinic and associated financial 
constraints. 
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Patients were recruited based on time of initiation of ART which was determined from 
records of patients initiated on ART maintained at the NACO-ART centre. A list of 
patients was made and they were actively recruited at the due time of presentation to 
the ART centre which was also determined based on the documentation in the chart at 
the previous visit. Outcomes were followed up in a systematic manner at follow up 
visits to the ID clinic or ART centre.  
 
The study was approved by the institutional review board (IRB) of our hospital in the 
month of November 2013. Following approval of the study protocol, the study was 
commenced from January 2014. 
 
5.6 STATISTICAL ANALYSIS 
 
The data was analysed for association between outcomes (alive or dead) and the modified 
VACS index (MVI) and the components of the MVI viz. age, sex, CD4 cell count, 
haemoglobin, AST, ALT, platelet count and serum creatinine using a logistic regression 
analysis; if any association was detected, the statistical significance would be ascertained 
from the p-value (< 0.05) and the 95 % confidence interval. The predicted mortality would 
be calculated with the aid of this logistic regression analysis and compared with the actual 
mortality in the study cohort after a 2 year period utilising a standardised mortality ratio. 
 Bi-variate analysis was performed between all the individual parameters (and the composite 
indices – eGFR and the FIB-4) and the outcome at the end of the study period. Outcomes 
considered were alive  at the end of 2 years as compared to death or lost to follow up which 
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grouped together as a bad outcome. The variables which showed the greater association were 
utilised for the logistic regression analysis for calculation of a predicted probability of  bad 
outcomes. 
All calculations and analysis were done using SPSS version 16.0. Initial tabulation of 
data was done using an excel spread sheet. Extensive statistical assistance was 
required during this project for which the author is indebted to the team of statisticians 
who assisted in this project. 
 
 
A flow diagram representing the study design and the timeline of the study has been 
presented as in Figure1:  
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Figure 1a. Timeline of the Study 
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Figure 1b: STROBE FIGURE 
 
 
 
 
 
  
Patients recruited from referrals to the NACO 
– ART centre from the Infectious Diseases 
(ID) clinic 
251 patients were recruited into the study 
251 patients included in the final analysis 
 
1. Satisfied inclusion criteria 
2. Satisfied exclusion criteria 
22 
2Sat 
From 1
st
 June 2012 to 31
st
 May 2013 
From 1
st
 June 2013 to 31
st
 May 2015 
 
13 deaths and 45 patients 
lost to follow up 
193 patients alive at end of 
study period 
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5.7 DIAGNOSTIC ASSAYS 
 
HIV testing was carried out as per WHO / NACO strategy III. The 1
st
 and 2
nd
 assays 
were 4
th
 generation assays which detect p24 antigen and antibody. The 3
rd
 assay was a 
2
nd
 generation assay which was used to differentiate between HIV-1 and HIV-2. In 
case of discrepancy between the 3 assays, additional assays including plasma HIV-1 
RNA estimation was carried out. 
 
CD-4 testing was carried out in a BD FACS count machine as per the manufacturer’s 
instruction. Briefly, 3 ml of the samples were collected in EDTA tubes between 8 AM 
and 10 AM. After collection of the sample, they were adequately mixed and 50 µl of 
patient’s samples were added into each of the reagent tubes, incubated at room 
temperature for 60 to 120 minutes. Following this, 50 µl of fixative solution was 
added and the reading was taken in the instrument with FACS count CD-3 / CD-4 
SW, version 1.0 software. Appropriate quality control with previous days’ low count, 
high count and commercially available stabilised blood samples were also carried out 
on each day. 
 
Detection of HCV – Ab was done using a 3rd generation enzyme-linked 
immunosorbent assay (ELISA) (UBI HCV EIA 4.0) and /or AXSYM (HCV version 
3.0). Results were deduced based on cut-off absorbance value calculated for each 
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ELISA run. All sample above the cut-off absorbance value were considered positive 
by ELISA. The signal: cut-off ratio (S/CO) was calculated automatically by the 
AXSYM. Sample with a ratio of >1.0 were considered to be positive by AXSYM as 
per the manufacturer’s instruction. 
 
Liver function parameters were estimated using IFCC approved method. 
Transaminases (AST & ALT) methods were an adaptation of the recommended 
procedure of the IFCC as described by Bergmeyer. 
 
Haemoglobin and platelet counts were estimated from EDTA blood samples using an 
automated haematology analyser. 
 
Records of all blood investigations are maintained in the electronic medical records 
which can be viewed only by authorised medical personnel. All records were 
tabulated to calculate the modified VACS index from an online calculator.(53) The 
mortality rate for 5 years is automatically calculated at the time of score generation. 
This would aid in predicting mortality in case of extending the duration of the study. 
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6. RESULTS   
 
  The time period for recruitment of patients for our study extended from 1st June 2012 
and extended until 31
st
 May 2013. All patients who were initiated on ART during this 
period were detected from the registry maintained at the ACTFID ART centre of our 
institution. Patients were retrospectively recruited into our study after informed 
consent. They were then actively followed up for a period of 2 years extending from 
1
st
 June 2013 to 31
st
 May 2015. At the end of the study period, the outcomes were 
tabulated to detect associations with individual variables and the modified VACS 
index. 
 
A total of 251 patients were recruited into the study at the end of the study period. The 
baseline characteristics of the individuals in the population are as given below: 
 
6.1 BASELINE CHARACTERISTICS 
 
The baseline characteristics of our study cohort are as listed below in the table. On 
further analysing the baseline characteristics, it can be seen that the mean age group of 
the cohort was a middle-aged, male predominant age group. The variables were 
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divided into two groups - the patients who were later found to be in the 
‘Unfavourable’ outcomes group and the ‘Alive’ group. 
 
The mean age of the patient in the ‘Unfavourable’ outcomes group was 39.88 ± 12.93 
years as compared to the ‘Alive’ group in which the mean age was found to be 38.09 
(10.98) years. The difference between the mean ages of both the groups was not 
statistically significant.  
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Figure 2. Comparison of Age and Sex in Unfavourable and Alive groups 
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Table 3. Baseline characteristics of the Unfavourable and Alive groups 
 
Unfavourable 
58 (23.1%) 
Alive 
193 (76.9%) 
 
Variables n Median (IQR) n Median (IQR) 
P 
value* 
CD4 58 
140.50 
(46.00,270.50) 
193 
258.00 
(146.50,354.00) 
.000 
Hb 58 11.00 (9.90,12.83) 189 12.00 (10.40,13.65) .075 
AST 52 31.50 (21.00,54.00) 154 26.00 (19.00,45.25) .150 
ALT 54 19.50 (11.00,29.50) 184 15.00 (11.25,28.75) .290 
Platelets 49 
225.00 
(163.50,267.00) 
143 
207.00 
(163.00,258.00) 
.547 
FIB4 48 1.29 (0.99,2.13) 131 1.21 (0.80,2.18) .446 
Creatinine(mg/dl) 53 1.02 (0.88,1.16) 190 0.96 (0.80,1.12) .141 
Creatinine(mmol/l) 53 90.17 (77.35,102.99) 190 84.86 (70.72,99.23) .142 
eGFR 51 76.00 (67.00,88.00) 181 80.00 (69.00,91.00) .322 
Age: mean(sd)  58 39.88 (12.93) 193 38.09 (10.98) 0.298
#
 
Sex: n(%)      
Female 24 (20.3) 94 (79.7) 0.327
$
 
Male 34 (25.6) 99 (74.4)  
HCV: n(%)      
Positive 0 (0) 1 (100.0) 1.000
@
 
Negative 45 (26.5) 125 (73.5)  
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Figure 4.Comparison of CD-4 in Unfavourable and Alive groups 
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The mean CD – 4 cell count in the ‘Unfavourable’ outcomes group was 140.50 cells 
/µL (IQR = 46.00 - 270.50) as compared to 258.00 cells /µL (IQR=146.50 - 354.00) in 
the ‘Alive’ group. The difference between the two groups was statistically significant 
(P-value=0.000). 
 
There was only a single patient who tested positive for HCV but this patient was 
present in the ‘Alive’ group. There was no significant difference between AST, ALT, 
Platelets counts, creatinine, eGFR or FIB-4 between both the groups.  
 
The haemoglobin levels between both the groups was not statistically very different as 
displayed by a mean Hb level of 11.00 g/dl (IQR=9.90-12.83) in the ‘Unfavourable’ 
outcomes group and 12.00 g/dl (IQR=10.40-13.65) in the ‘Alive’ group with a P-value 
of 0.075. 
 
Each of the baseline characteristics were also grouped as per the stratification of the 
modified VACS Index. This table (Table4) is also displayed as below : 
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Table 4. Baseline Characteristics stratified as per VACS Index scoring system 
Age < 50 215 
 
50 – 65 
 
31 
 
 
≥ 65 
 
5 
 
 
Total 251 
100.0% 
 
CD – 4 ≥ 500 
 
28 
 
 
200 – 499 
 
118 
 
 
100 – 199 
 
51 
 
 
50 – 99 
 
23 
 
 
< 50 
 
31 
 
 
Total 251 
100.0% 
 
Haemoglobin ≥ 14 
 
44 
 
 
12.0 – 13.9 
 
74 
 
 
10.0 – 11.9 
 
78 
 
 
< 10.0 
 
51 
 
 
79 
 
Total 247 
100.0% 
 
eGFR ≥ 60 
 
213 
 
 
45.0 – 59.9 
 
13 
 
 
30.0 – 44.9 
 
4 
 
 
< 30 
 
2 
 
 
Total 232 
100.0% 
 
FIB - 4 < 1.45 
 
102 
 
 
1.45 – 3.25 
 
54 
 
 
> 3.25 
 
23 
 
 
Total 179 
100.0% 
 
Hepatitis C Positive 1 
 
Negative 170 
Total 171 
100.0% 
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At the end of the study period on 31
st
 May 2015, the outcomes of patients were 
tabulated against the baseline blood parameters and Modified VACS Index (MVI) 
scores. Each of the baseline blood parameters were analysed individually with the 
final outcome of the patient to detect association with an unfavourable outcome. The 
MVI was also analysed with the final outcome to detect an association with an 
unfavourable outcome.  
 
A receiver operating curve (ROC) was also plotted to detect the discriminant function 
of the MVI to detect the probability of an unfavourable outcome. The best cut-off 
value for the predicted probability of an unfavourable outcome was calculated 
following a logistic regression analysis. This value was compared with the actual 
mortality at the end of the 2 year study period to find out how well the predicted 
values correlated with the actual values. 
 
The total number of deaths at the end of the study period was found to be 13 patients, 
with 45 patients being lost to follow up. For a logistic regression analysis, both the 
number of deaths and patients who were lost to follow up were put together in a group 
classified as “Unfavourable Outcomes”. For all the analyses, including the bivariate 
analysis as well as the logistic regression, this nomenclature was adhered to. Hence, at 
the end of the study period on 31
st
 May 2015, the total number of patients in the 
unfavourable outcome group was detected to be 58. The total number of patients 
confirmed to be alive at the end of the study period was 193. 
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As mentioned in the above paragraph, each of the individual constituent parameters of 
the MVI was cross-tabulated with the final outcome using a bivariate analysis. The 
outcomes which displayed a significant association with an unfavourable outcome 
were employed for the logistic regression analysis. The Modified VACS Index was 
also cross tabulated with the outcomes to detect a possible correlation. 
6.2 PRIMARY OUTCOME 
 
At the end of the analysis, which was done with the aid of a team of expert 
statisticians, the MVI scores were studied both in the ‘Alive’ and ‘Unfavourable’ 
outcomes group. The results are as tabulated below: 
 
Table5. The Modified VACS Index scores in Unfavourable and Alive Groups 
 
 
 
Outcome Number Mean 
MVI score 
SD SEM 
Unfavourable 
(Dead/LFU) 
58 
 
44.8103 22.46358 2.94961 
 
Alive 193 31.7306 20.39250 1.46788 
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On studying the above data, it is evident that there is a difference in the MVI scores of 
both the groups. The mean MVI score in the ‘Alive’ group was 31.7306 ± 20.39250 as 
compared to 44.8103 ± 22.46358 in the ‘Unfavourable’ group.  
 
This difference was found to be significant using an Independent Samples T-Test as 
displayed in the annexures. This implies that a mean higher score was consistently 
found in the group with the ‘Unfavourable’ outcomes as compared to the ‘Alive’ 
group which was clinically significant, at the end of a 2 year analysis. 
 
 
 
Figure 5a. Comparison of the Modified VACS Index in Unfavourable and Alive groups 
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Figure 6a. Comparison of the Modified VACS Index in Unfavourable and Alive groups 
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6.3 SECONDARY OUTCOMES  
 
In the next analysis, an ROC curve was plotted using the data bank derived from the 
study. For the logistic regression analysis, of all the variables analysed, only CD4 was 
significantly associated with an adverse outcome. Other variables utilised for the 
logistic regression analysis were age, creatinine and AST based on the best possible 
association.  
 
Table6. Variables Employed for Logistic Regression Analysis 
 
  
B S.E. Wald df Sig. Exp(B) 
95.0% C.I.for 
EXP(B) 
  Lower Upper 
 CD-4 .058 .016 12.621 1 .000 1.059 1.026 1.093 
Age .030 .031 .938 1 .333 1.031 .969 1.097 
Creatinine .176 .146 1.457 1 .227 1.192 .896 1.587 
AST .003 .003 1.026 1 .311 1.003 .997 1.008 
Constant -2.295 .362 40.126 1 .000 .101   
     
 
 
In order to find the predictive probability (expected proportion of adverse outcomes), 
predicted probabilities were computed using the above results. This is like a score 
ranging from a 0 to 1 scale or 0 to 100%. These were correlated/associated with the 
outcome.  
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For the probability value of 0.1845, the sensitivity was found to be 70% and the 
specificity was found to be 58%. This value of the predicted probability was chosen as 
the best cut off value and was used to construct the following 2 x 2 table to calculate 
the validity statistics and the positive predictive values.  
 
Table7. 2X 2 table for construction of ROC Curve 
Predicted Status Actual Status 
Unfavourable Alive Total 
 
Unfavourable 
 
35 65 100 
Alive 
 
15 88 103 
 
Total 
50 153 203 
 
 
The sensitivity was calculated to be 70% and the specificity was estimated to be 58%. 
The positive predictive value was calculated to be 35% and the negative predictive 
value was found to be 85.4%. 
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Figure 7. Receiver Operating Curve of the Modified VACS Index 
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The ROC curve was plotted as shown in the figure above. The C – statistic of the 
curve was calculated to be 0.66. The c statistic conveys how well a model can 
discriminate between observations at different levels of the outcome. It is the same as 
the area that lies under the receiver-operating characteristic curve, formed by taking 
the predicted values from the regression model as a diagnostic test for the event in the 
data. The minimum value of c is 0.5; the maximum is 1.0. A C-statistic of 0.7 to 0.8 to 
show acceptable discrimination, values of 0.8 to 0.9 to indicate excellent 
discrimination, and values of ≥ 0.9 show outstanding discrimination. This implies that 
the discriminant function of the modified VACS index is below acceptable 
discriminant function. 
 
The best cut-off of predicted mortality was found to be 0.1845 or 18.45 %. After 2 
years, the total number of confirmed deaths was calculated to be 13; hence, the actual 
mortality rate after 2 years was calculated to be 5.17 %. This implies that the ratio 
of the observed to actual mortality would be 28 % (0.28), which is lesser than 
predicted by the modified VACS index. 
 
As mentioned previously, of all the constituent baseline parameters of the modified 
VACS index, only the CD-4 was found to have a significant association with an 
unfavourable outcome.  
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Table8. CD-4 count of cohort stratified as per VACS scoring system 
 
CD-4 
(per cu. mm) 
Outcome Total 
Unfavourable Alive 
 
≥ 500 
 5 23 28 
 (17.9%) (82.1%) (100.0%) 
200 – 499 
 18 100 118 
 (15.3%) (84.7%) (100.0%) 
100 – 199 
 11 40 51 
 (21.6%) (78.4%) (100.0%) 
50 – 99 
 8 15 23 
 (34.8%) (65.2%) (100.0%) 
< 50 
 16 15 31 
 (51.6%) (48.4%) (100.0%) 
Total 
 
 
58 
 
193 
 
251 
  (23.1%) (76.9%) (100.0%) 
 
 
 
 
 
 
 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square 20.539
a 4 .000 
Likelihood Ratio 18.452 4 .001 
Linear-by-Linear 
Association 
17.445 1 .000 
N of Valid Cases 
251   
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The significance of the association between CD-4 and adverse outcomes was 
determined by Chi-Square testing as displayed in the table above.  
 
None of the other individual constituent variables or the composite markers (eGFR 
and FIB-4) showed a significant correlation with adverse outcomes. This was 
demonstrated by Chi-Square testing in case of age, haemoglobin, eGFR and FIB-4. 
Scatter plots and independent samples T-testing was done for detecting associations 
between AST, ALT, platelets and creatinine and adverse outcomes. 
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7. DISCUSSION 
 
At the end of a two year follow up of a cohort of patients of diverse age groups with 
an underlying HIV infection and initiated on ART, we found that there was a 
significant difference in the Modified VACS Index (MVI) Scores between the patients 
who were alive and the patients in the ‘Unfavourable’ outcome group which was a 
composite of death and patients who were lost to follow up at the end of a two year 
follow up period.  
 
But, the discriminant function of the MVI score as a prognostic score is not optimal as 
explained by a ROC curve with a c-statistic of 0.66. The sensitivity of the MVI was 
calculated to be 70% and the specificity was estimated to be 58%. The positive 
predictive value was determined to be 35% and the negative predictive value was 
found to be 85.4%. The predicted mortality was found to be higher than the observed 
mortality at the culmination of the study period. This may be attributed to better 
compliance with anti-retroviral therapy with optimum monitoring for side effects of 
therapy. 
 
The differences in a Western population in which the original VACS Index was 
validated, and an Indian population, include risk factors, age group at risk and causes 
of mortality. In an Indian population which has predominantly opportunistic 
infections, drug toxicity and complications like IRIS as the causes of mortality, a 
91 
 
variable like HCV infection does not act as a precise indicator of morbidity and 
mortality in the generalised population. In addition, the index does not take into 
account the type of ART the patient has been initiated on, underlying cardiovascular 
risk factors, sequelae of previous opportunistic infections, nutritional status and socio-
economic status, all of which act as potent barriers in assessing prognosis in PLHIV. 
We had a total of 13 deaths and 45 patients lost to follow up after a two year study 
period. If we take into account all the documented deaths in our cohort over a two 
year span, we find varied causes of death in these patients. The causes of mortality in 
all 13 patients who died are as tabulated in Table 9: 
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Table9.  Causes of mortality in all confirmed deaths 
Serial No. Cause of death 
Patient 1  WHO CLINICAL STAGE IV -
Clinical and immunological failure 
to 1
st
 line ART. 
 Disseminated Tuberculosis 
Patient 29  Decompensated chronic liver 
disease – Ethanol related 
 Bacterial peritonitis 
 Septic shock 
Patient 30  WHO Clinical Stage-IV 
 Hepatitis B Co-infection 
 Disseminated TB 
 Anaemia of Chronic Disease 
 Chronic Liver Disease-Ascites 
Patient 31  WHO Clinical Stage-IV 
 Disseminated TB 
 Oral Candidiasis 
Patient 69  Pulmonary TB in septic shock 
Patient 80  WHO Clinical Stage-IV  
 Pseudomonas  sepsis 
 Septic shock with multi organ 
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dysfunction syndrome (MODS) 
 Severe neutropenia  
 Hypokalaemia 
Patient 110  Disseminated TB 
Patient 113  WHO Clinical Stage-IV 
 TB Meningitis- Communicating 
hydrocephalus post right 
ventriculo-peritoneal shunt 
 Brain stem infarct 
Patient 135  WHO Clinical Stage-IV 
 Hepatitis B co-infection 
 Right middle lobe pneumonia 
 Pulmonary embolism 
 Zidovudine induced neutropenia 
Patient 161  WHO Clinical Stage-IV  
 Chronic Diarrhoeal Disease- 
Cytomegalovirus related 
 Disseminated Cytomegalovirus 
Infection 
Patient 183  WHO Clinical Stage-IV 
 Disseminated TB 
Patient 210  WHO Clinical Stage-IV 
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 Disseminated TB 
Patient 219  WHO Clinical Stage-IV 
 Hodgkin’s Lymphoma- STAGE 
IV B 
 Type 2 Diabetes Mellitus 
 
 
As it can be seen from the table, the majority of deaths occurred in severe disease 
(WHO Clinical Stage-IV). Also, a significant majority of the deaths had an 
opportunistic infection, which in our community happens to be tuberculosis, which is 
rampant even amongst individuals whose immunity is quite robust. 
 
Two of the deaths had alcoholic liver disease as an underlying comorbidity. But, the 
non- inclusion of tuberculosis or opportunistic infections in the index leaves a lacuna 
in the baseline objective assessment in a PLHIV in an Indian context. 
 
In the original VACS cohort, the study had shown a nearly 20 – fold difference 
between the estimated 5 year mortality of individuals with a VACS score < 10 as 
compared to an individual with a VACS score ≥ 60 ( 5-year mortality of 2.8% as 
compared to 55% respectively). In the ART-CC study, the difference between the two 
categories was found to be even more profound (5-year mortality of 1.6% if VACS 
score < 10 as compared to 41% for a VACS score ≥ 60). 
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It has to be kept in mind that the original index had the 5-year mortality which was 
assessed at baseline as compared to our study where the timeline was for 2 years. The 
study is to be advanced for another 3 years to detect a significant correlation between 
the modified VACS index and the outcome. 
 
Another major factor which may hinder the discriminant factor of the MVI was the 
absence of the HIV RNA-PCR which may have added strength to the index. The 
rationale behind the exclusion of the same was the financial constraints most patients 
in our hospital settings face in their medical expenses.  
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8. LIMITATIONS 
 
There were a few limitations of our study which may have impacted the final result. 
Great care was adopted to limit the possibility of errors in this study. Some of the 
salient drawbacks are listed below: 
 
• The HIV RNA-PCR was excluded from the modified index as compared to the 
original index. This may have reduced the discriminant factor of the modified 
VACS index. This was excluded as the HIV RNA-PCR is an expensive test and 
is not performed on a routine basis in the ID clinic. The rationale for exclusion 
of this investigation was to find a good prognostic index correlating with 
mortality and to be affordable to a patient from a low to middle socio-economic 
status (SES) which we believe represents the vast majority of patients attending 
the ID clinic and ACTFID ART centre.  
 
As compared to the original VACS index which was validated in a cohort of 
US military veterans which is well funded and supported with a robust health 
network, our cohort mostly hails from a predominantly lower to middle socio-
economic status from a rural backdrop. Knowledge about the HIV pandemic 
has not yet permeated down to people from remote villages but, awareness 
amongst the population cohort attending the ID clinic and ART centre  
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• There were a significant number of patients lost to follow up in our study 
which may have distorted the outcomes of the study and may have swayed the 
discriminant factor of the modified VACS index to a less than acceptable c-
statistic. This may even affect the study in a way so as to hinder the study of 
the causes of mortality in patients in whom death was reported as the final 
outcome.  
 
Measures were adopted to trace the patients who were lost to follow up by 
using the contact details mentioned in the hospital records. Home visit workers 
were employed to trace the missing patients. The missing patients had either 
emigrated to other places outside the boundary of Tamil Nadu or the address 
details had changed and had not been updated, hindering our efforts to contact 
them. 
 
 
• Another drawback of the study was the fact that our cohort was retrospectively 
chosen from the time of the study. Our cohort was taken from the time period 
dating from 1st June 2012 to 31st May 2013. The same cohort was followed up 
from 1st June 2013 to 31st May 2015. This resulted in a number of missing 
investigations which may have had an impact on the final results of the study. 
 
98 
 
The ideal method of conducting the study would have been to prospectively 
recruit patients but due to the constraints of a limited follow up period if done 
in such a manner, it was decided to recruit a cohort retrospectively and follow 
the outcomes after a two year study period. The study can be further extended 
for a three year duration to match the exact five year mortality with the 
expected five year outcome as calculated using the modified VACS Index. 
 
Since the investigations we collected were potentially modified after the 
initiation of ART, hence it was not possible to prospectively collect blood 
investigations from the date of recruitment for further analysis. These 
drawbacks will help in formulating a validation study of the MVI in the future 
in which the sample cohort may be prospectively recruited with ideally no 
missing blood parameters and potentially new added variables such as 
tuberculosis or candidiasis at the time of diagnosis. Thresholds for the MVI 
may need to be redefined for an Indian sample cohort due to regional variations 
as compared to the original validation cohorts. 
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9. CONCLUSIONS 
 
From our study, we have seen that the modified VACS Index has a sub-optimal 
discriminant function to predict mortality after a two year study period in a South 
Indian HIV infected population who have been initiated on ART. But, the score 
between the ‘Alive’ and ‘Unfavourable’ outcomes are significantly different; there is a 
clear demarcation between the scores of both the groups. 
 
The only variable of the MVI which showed a significant association with mortality 
was the CD-4 count which was employed in the logistic regression to show the 
predicted mortality after a two year study period. 
 
We recommend extending the study for another three years to compare the predicted 
five year mortality rate as per the modified VACS index with the actual mortality rate 
after following up the same cohort of patients. 
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ANNEXURES 
Annexure-1 :STATISTICAL ANALYSIS 
 
 
Some list of data to check the Coding: 
slno  age_V   CD4_V   hb_V  egfr_v fib4_V score1  outcome_new  
1.00    .00   29.00   38.00    .00     6.00    73.00      1.00        
2.00    .00   10.00   38.00    .00      .00    48.00      2.00        
3.00     12.00    6.00    38.00     26.00   .00    82.00      1.00          
4.00    .00      10.00    38.00    .00      .00    48.00      2.00          
5.00    .00       6.00    22.00    .00      .00    28.00      2.00          
6.00    .00       28.00   10.00    .00      .00    38.00      2.00  
 
       
Cross tabulations with outcome (Alive vs others). 
 
 
age_V * outcome_new 
 
 
Crosstab 
 outcome_new Total 
Dead Alive 
age_V 
.00 
Count 47 168 215 
% within age_V 21.9% 78.1% 100.0% 
12.00 
Count 9 22 31 
% within age_V 29.0% 71.0% 100.0% 
27.00 
Count 2 3 5 
% within age_V 40.0% 60.0% 100.0% 
Total 
Count 58 193 251 
% within age_V 23.1% 76.9% 100.0% 
 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square 1.604
a
 2 .449 
Likelihood Ratio 1.478 2 .478 
Linear-by-Linear Association 1.591 1 .207 
N of Valid Cases 251   
 
a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 1.16. 
 
 
 
CD4_V * outcome_new 
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Crosstab 
 outcome_new Total 
Dead Alive 
CD4_V 
.00 
Count 5 23 28 
% within CD4_V 17.9% 82.1% 100.0% 
6.00 
Count 18 100 118 
% within CD4_V 15.3% 84.7% 100.0% 
10.00 
Count 11 40 51 
% within CD4_V 21.6% 78.4% 100.0% 
28.00 
Count 8 15 23 
% within CD4_V 34.8% 65.2% 100.0% 
29.00 
Count 16 15 31 
% within CD4_V 51.6% 48.4% 100.0% 
Total 
Count 58 193 251 
% within CD4_V 23.1% 76.9% 100.0% 
 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square 20.539
a
 4 .000 
Likelihood Ratio 18.452 4 .001 
Linear-by-Linear Association 17.445 1 .000 
N of Valid Cases 251   
 
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 5.31. 
 
 
 
hb_V * outcome_new 
 
 
Crosstab 
 outcome_new Total 
Dead Alive 
hb_V 
.00 
Count 5 39 44 
% within hb_V 11.4% 88.6% 100.0% 
10.00 
Count 18 56 74 
% within hb_V 24.3% 75.7% 100.0% 
22.00 
Count 19 59 78 
% within hb_V 24.4% 75.6% 100.0% 
38.00 
Count 16 35 51 
% within hb_V 31.4% 68.6% 100.0% 
Total 
Count 58 189 247 
% within hb_V 23.5% 76.5% 100.0% 
 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square 5.426
a
 3 .143 
Likelihood Ratio 5.923 3 .115 
Linear-by-Linear Association 4.141 1 .042 
N of Valid Cases 247   
 
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 10.33. 
 
 
 
egfr_v * outcome_new 
 
 
Crosstab 
 outcome_new Total 
Dead Alive 
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egfr_v 
.00 
Count 44 169 213 
% within egfr_v 20.7% 79.3% 100.0% 
6.00 
Count 4 9 13 
% within egfr_v 30.8% 69.2% 100.0% 
8.00 
Count 2 2 4 
% within egfr_v 50.0% 50.0% 100.0% 
26.00 
Count 1 1 2 
% within egfr_v 50.0% 50.0% 100.0% 
Total 
Count 51 181 232 
% within egfr_v 22.0% 78.0% 100.0% 
 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square 3.550
a
 3 .314 
Likelihood Ratio 3.022 3 .388 
Linear-by-Linear Association 2.731 1 .098 
N of Valid Cases 232   
 
a. 5 cells (62.5%) have expected count less than 5. The minimum expected count is .44. 
 
 
 
 
 
 
 
 
fib4_V * outcome_new 
 
 
Crosstab 
 outcome_new Total 
Dead Alive 
fib4_V 
.00 
Count 27 75 102 
% within fib4_V 26.5% 73.5% 100.0% 
6.00 
Count 14 40 54 
% within fib4_V 25.9% 74.1% 100.0% 
25.00 
Count 7 16 23 
% within fib4_V 30.4% 69.6% 100.0% 
Total 
Count 48 131 179 
% within fib4_V 26.8% 73.2% 100.0% 
 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square .181
a
 2 .913 
Likelihood Ratio .178 2 .915 
Linear-by-Linear Association .138 1 .710 
N of Valid Cases 179   
 
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 6.17. 
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AST and Score: 
 
 
 
t-test   groups = outcome_new(1,2) / variables =  AST / criteria = ci(.95). 
 
 
 
T-Test 
 
 
[DataSet1] C:\JEY\Medicine\Adithya\Adhitya_29Jun15.sav 
 
 
Group Statistics 
 outcome_new N Mean Std. Deviation Std. Error Mean 
AST 
Dead 52 53.33 84.874 11.770 
Alive 154 39.95 47.162 3.800 
 
 
Independent Samples Test 
 Levene's Test for Equality of Variances t-test for Equality of Means 
F Sig. t df Sig. (2-tailed) Mean Difference Std. Error Difference 95% Confidence Interval of the Difference 
Lower Upper 
AST 
Equal variances assumed 2.852 .093 1.416 204 .158 13.379 9.447 -5.247 32.005 
Equal variances not assumed   1.082 61.964 .284 13.379 12.368 -11.345 38.103 
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ALT and Score: 
 
 
 
t-test groups = outcome_new(1,2) / variables = ALT / criteria = ci(.95). 
 
 
T-Test 
 
[DataSet1] C:\JEY\Medicine\Adithya\Adhitya_29Jun15.sav 
 
 
Group Statistics 
 outcome_new N Mean Std. Deviation Std. Error Mean 
ALT 
Dead 54 28.30 40.104 5.457 
Alive 184 26.03 29.220 2.154 
 
 
Independent Samples Test 
 Levene's Test for Equality of Variances t-test for Equality of Means 
F Sig. t df Sig. (2-tailed) Mean Difference Std. Error Difference 95% Confidence Interval of the Difference 
Lower Upper 
ALT 
Equal variances assumed .001 .977 .458 236  .647 2.269 4.951 -7.484 12.023 
Equal variances not assumed   .387 70.307 .700 2.269 5.867 -9.432 13.970 
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Platelets and Score: 
 
 
 
 
 
t-test   groups = outcome_new(1,2) / variables = Platelets / criteria = ci(.95). 
T-Test 
[DataSet1] C:\JEY\Medicine\Adithya\Adhitya_29Jun15.sav 
Group Statistics 
 
outcome_new N Mean Std. Deviation Std. Error Mean 
Platelets 
Dead 49 222.35 96.605 13.801 
Alive 143 215.98 96.282 8.052 
 
Independent Samples Test 
 
Levene's Test for Equality of Variances t-test for Equality of Means 
F Sig. t df Sig. (2-tailed) Mean Difference Std. Error Difference 95% Confidence Interval of the Difference 
Lower Upper 
Platelets 
Equal variances assumed .155 .694 .399 190 .690 6.368 15.951 -25.097 37.832 
Equal variances not assumed 
  
.399 82.987 .691 6.368 15.978 -25.411 38.147 
112 
 
 
Creatinine (mg/dl) and Score : 
 
It appears as though there are couple of outliers. However, no correlation. 
 
t-test groups = outcome_new(1,2) / variables =  Creatmgdl  / criteria = ci(.95). 
 
T-Test 
 
[DataSet1] C:\JEY\Medicine\Adithya\Adhitya_29Jun15.sav 
Group Statistics 
 
outcome_new N Mean Std. Deviation Std. Error Mean 
Creatmgdl 
Dead 53 1.3715 2.59104 .35591 
Alive 190 1.0089 .46227 .03354 
Independent Samples Test 
 
Levene's Test for Equality of Variances t-test for Equality of Means 
F Sig. t df Sig. (2-tailed) Mean Difference Std. Error Difference 95% Confidence Interval of the Difference 
Lower Upper 
Creatmgdl 
Equal variances assumed 7.047 .008 1.836 241  .068 .36256 .19748 -.02645 .75157 
Equal variances not assumed 
  
1.014 52.926 .315 .36256 .35748 -.35448 1.07961 
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ROC Curve of Score with Outcome (Dead vs Others). 
 
 
T-Test 
 
Group Statistics 
 
outcome_new N Mean Std. Deviation Std. Error Mean 
score1 
Dead 58 44.8103 22.46358 2.94961 
Alive 193 31.7306 20.39250 1.46788 
Independent Samples Test 
 
Levene's Test for Equality of Variances t-test for Equality of Means 
F Sig. t df Sig. (2-tailed) Mean Difference Std. Error Difference 95% Confidence Interval of the Difference 
Lower Upper 
score1 
Equal variances assumed 2.596 .108 4.182 249  .000 13.07977 3.12733 6.92039 19.23916 
Equal variances not assumed 
  
3.970 87.142         .000 13.07977 3.29468 6.53140 19.62815 
 
Syntax: 
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**** Weights for AGe. 
*****  V implies VACS Index. 
if  (age <50) age_V=0. 
if (age >=50 and age <=64 ) age_V=12. 
if (age >=65) age_V=27. 
exec. 
freq age_v. 
 
* CD4 Weights. 
****** VACS weights. 
 
If (cd4 >= 500) CD4_V=0. 
if (cd4>=350 and cd4 <=499 )cd4_V=6. 
if (cd4>=200 and cd4 <=349 )cd4_V=6. 
if (cd4>=100 and cd4 <=199 )cd4_V=10. 
if (cd4>=50 and cd4 <=99 )cd4_V=28. 
If (cd4 <50) CD4_V=29. 
exec. 
freq cd4_v. 
 
 
*******   Hemoglobin. 
if (hb >=14) hb_V=0. 
if (hb >=12 and hb <= 13.9) hb_v=10. 
if (hb >=10 and hb <= 11.9) hb_v=22. 
if (hb <10) hb_V=38. 
exe. 
freq hb_v. 
**** . 
 
 
***** FIB 4. 
if (fib4 <1.45) fib4_V=0. 
if (fib4 >=1.45 and fib4 <=3.25) fib4_v=6. 
if (fib4 >3.25 ) fib4_V =25. 
exec. 
freq fib4_v. 
 
 
***** eGFR. 
if (egfr >=60) egfr_v =0. 
if (egfr >=45 and egfr<=59.9) egfr_v=6. 
if (egfr >=30 and egfr <=44.9) egfr_v=8. 
if (egfr <30 ) egfr_v=26. 
exec. 
freq egfr_v. 
 
Outcome: 
 
if (outcome = "Alive" ) outcome_new =2. 
if (outcome = "Death")outcome_new=1. 
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if (outcome = "LFU" ) outcome_new =1. 
val lab outcome_new  1 "Dead" 2 "Alive". 
exec. 
freq outcome_new. 
 
 
 
compute score1 = sum (age_v, cd4_v, HB_v , egfr_v, fib4_v). 
exec. 
mean score by outcome_new/ stat= anova . 
 
Further analyses to find the Predictive value of a Model: 
Note : Death and LFU combined together as bad outcome for the following analyses. 
 
Based on the bi-variate analyses, I have chosen 4 variables. That are: CD4, Creatinine, AST and Age. 
Though the age was not at all significant (very high p value), due to biological reason this was 
included. Of these 4 variables, only CD4 is significant. The following is the results of Logistic 
Regression analysis. 
 
Variables in the Equation 
  
B S.E. Wald df Sig. Exp(B) 
95.0% C.I.for EXP(B) 
  Lower Upper 
Step 1
a
 CD4_V .058 .016 12.621 1 .000 1.059 1.026 1.093 
age_V .030 .031 .938 1 .333 1.031 .969 1.097 
Creatmgdl .176 .146 1.457 1 .227 1.192 .896 1.587 
AST .003 .003 1.026 1 .311 1.003 .997 1.008 
Constant -2.295 .362 40.126 1 .000 .101   
a. Variable(s) entered on step 1: CD4_V, age_V, Creatmgdl, AST.     
 
In order to find the predictive probability (expected proportion of bad outcomes), predicted 
probabilities were computed using the above results. This is like a score ranging from 0 to 1 scale or 
0 to 100%. These were correlated/associated with the outcome. The following table presents the 
predicted probabilities against outcome. 
 
Coordinates of the Curve 
Test Result Variable(s):Predicted probability 
Positive if Greater 
Than or Equal To
a
 Sensitivity 1 - Specificity 
.0000000 1.000 1.000 
.1053703 1.000 .993 
.1061755 1.000 .987 
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.1072590 1.000 .980 
.1086935 .980 .980 
.1098943 .980 .974 
.1109311 .960 .974 
.1115071 .960 .967 
.1134248 .960 .961 
.1150867 .960 .954 
.1165893 .960 .948 
.1195137 .960 .941 
.1250367 .960 .935 
.1309920 .960 .928 
.1385451 .940 .928 
.1442989 .940 .922 
.1445493 .920 .922 
.1447670 .920 .915 
.1449521 .920 .908 
.1451458 .920 .902 
.1452262 .920 .895 
.1452881 .920 .889 
.1456930 .920 .882 
.1462225 .920 .876 
.1464901 .920 .869 
.1466334 .900 .869 
.1467581 .900 .863 
.1468641 .900 .856 
.1470703 .900 .850 
.1473580 .900 .843 
.1476085 .900 .837 
.1481989 .880 .837 
.1486769 .880 .830 
.1487235 .860 .830 
.1488350 .860 .824 
.1489906 .860 .817 
.1490979 .860 .810 
.1493805 .860 .804 
.1496336 .860 .797 
.1496718 .840 .797 
.1497247 .840 .791 
.1498177 .840 .784 
.1504287 .840 .778 
.1510612 .840 .771 
.1513212 .840 .765 
.1516693 .840 .758 
.1519601 .840 .752 
.1521227 .840 .745 
.1522169 .840 .739 
.1523649 .840 .732 
.1525774 .840 .725 
.1527212 .840 .719 
.1529147 .840 .712 
.1532269 .840 .706 
.1534252 .840 .699 
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.1534855 .840 .693 
.1537944 .840 .686 
.1543528 .820 .686 
.1548280 .820 .680 
.1552498 .820 .673 
.1554610 .820 .667 
.1560999 .800 .667 
.1570461 .800 .660 
.1574155 .780 .660 
.1576010 .780 .654 
.1580511 .780 .647 
.1587041 .760 .647 
.1594864 .760 .641 
.1599402 .760 .634 
.1600318 .760 .627 
.1601684 .760 .621 
.1605573 .760 .614 
.1613064 .760 .608 
.1627041 .760 .601 
.1637332 .740 .601 
.1639014 .740 .595 
.1645858 .740 .588 
.1659212 .720 .588 
.1667162 .720 .582 
.1669799 .720 .575 
.1676207 .700 .575 
.1681636 .700 .569 
.1689206 .700 .562 
.1697278 .700 .556 
.1701706 .700 .549 
.1707786 .700 .542 
.1712425 .700 .536 
.1720964 .700 .529 
.1734819 .700 .523 
.1748936 .700 .516 
.1767523 .700 .510 
.1779684 .700 .503 
.1783330 .700 .497 
.1787543 .700 .490 
.1791422 .700 .484 
.1794795 .700 .477 
.1801389 .700 .471 
.1808343 .700 .464 
.1813119 .700 .458 
.1821610 .700 .451 
.1828638 .700 .444 
.1831269 .700 .438 
.1835325 .700 .431 
.1845332 .700 .425 
.1853106 .680 .425 
.1854537 .680 .418 
.1859638 .660 .418 
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.1866658 .640 .418 
.1871780 .620 .418 
.1874812 .620 .412 
.1877318 .620 .405 
.1882161 .620 .399 
.1886730 .600 .399 
.1889247 .600 .392 
.1891256 .600 .386 
.1912403 .600 .379 
.1935645 .600 .373 
.1952873 .600 .366 
.1978080 .600 .359 
.1990730 .600 .353 
.1998274 .600 .346 
.2025574 .600 .340 
.2053961 .580 .340 
.2061782 .580 .333 
.2065482 .580 .327 
.2082629 .580 .320 
.2102411 .580 .314 
.2109914 .580 .307 
.2114007 .580 .301 
.2121242 .580 .294 
.2133679 .580 .288 
.2144094 .580 .281 
.2173867 .580 .275 
.2219800 .580 .268 
.2261475 .580 .261 
.2299274 .580 .255 
.2319418 .560 .255 
.2343094 .560 .248 
.2401359 .560 .242 
.2454488 .560 .235 
.2473430 .560 .229 
.2486437 .560 .222 
.2495817 .560 .216 
.2502328 .540 .216 
.2512395 .540 .209 
.2673648 .520 .209 
.2865111 .500 .209 
.2920300 .480 .209 
.3326268 .480 .203 
.3724331 .480 .196 
.3796284 .460 .196 
.3863475 .440 .196 
.3872241 .440 .190 
.3877890 .420 .190 
.3893991 .420 .183 
.3909810 .420 .176 
.3931631 .420 .170 
.3957594 .420 .163 
.3970783 .400 .163 
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.3990684 .400 .157 
.4007032 .380 .157 
.4011638 .380 .150 
.4019196 .360 .150 
.4024904 .360 .144 
.4028563 .360 .137 
.4032437 .360 .131 
.4033733 .360 .124 
.4051785 .360 .118 
.4070136 .360 .111 
.4094846 .340 .111 
.4124733 .340 .105 
.4135934 .340 .098 
.4142256 .340 .092 
.4148959 .320 .092 
.4155767 .300 .092 
.4167508 .300 .085 
.4180726 .280 .085 
.4190076 .280 .078 
.4200692 .280 .072 
.4207025 .280 .065 
.4223898 .260 .065 
.4264861 .240 .059 
.4298031 .240 .052 
.4345285 .220 .052 
.4397498 .200 .052 
.4437675 .200 .046 
.4487552 .180 .046 
.4510980 .160 .046 
.4547598 .140 .046 
.4640485 .140 .039 
.4702348 .140 .033 
.4766356 .140 .026 
.4907483 .140 .020 
.4990782 .120 .020 
.5009972 .100 .020 
.5058612 .100 .013 
.5099826 .100 .007 
.5175599 .100 .000 
.5246319 .080 .000 
.5646822 .060 .000 
.6927874 .040 .000 
.8277547 .020 .000 
1.0000000 .000 .000 
The test result variable(s): Predicted probability has 
at least one tie between the positive actual state 
group and the negative actual state group. 
a. The smallest cutoff value is the minimum observed 
test value minus 1, and the largest cutoff value is the 
maximum observed test value plus 1. All the other 
cutoff values are the averages of two consecutive 
ordered observed test values. 
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From the above table you could see for the probability value of .1845, the sensitivity was 70% and 
the specificity was 58%. If we choose this as the best cut off value then we could construct the 
following 2 x2 table to find the validity statistics and the Positive Predictive values.  
 
 
 
 
The following is nearly that table: 
Predicted Status Actual Status 
Dead+LFU Alive Total 
 
Dead+LFU 
 
35 65 100 
Alive 
 
15 88 103 
 
Total 
50 153 203 
 
The sensitivity is 70% and the Specificity is 58%. The positive predictive values is 35% and the 
negative predictive value is 85.4%. 
The  C statistics is .66. (this is the summary of ROC curve). 
 
The following is the ROC Curve. I am working on a nice curve with few points.  
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Annexure 6: DATA SHEET 
 
 
Sex CD4 ct. Hb AST ALT Platelets FIB-4 Creat(mg/dl)Creat(mmol/l)eGFR HCV MVI 5 yr MortalityOutcome
Female 42 9.9 93 52 196 2.43 0.98 86.632 68 Negative 73 50 Death
Female 160 9.8 26 14 218 1.21 1.03 91.052 64 Negative 48 25.5 Alive
Male 231 7.7 14 20 142 1.12 19.8 1750.32 3 Negative 82 58.4 LFU
Female 170 3.1 23 16 270 0.55 0.74 65.416 101 Negative 48 25.5 Alive
Female 325 11.2 17 12 233 0.55 0.78 68.952 95 NA 28/33 10.8/13.8 Alive
Female 82 12.6 36 29 253 0.82 0.96 84.864 72 Negative 38 17.3 Alive
Female 367 11.8 12 8 189 0.83 0.82 72.488 83 NA 28/33 10.8/13.8 Alive
Female 396 11 17 12 216 0.64 0.91 80.444 78 Negative 28 10.8 Alive
Female 44 11.6 34 13 50 8.3 0.8 70.72 83 Negative 51 28.3 Alive
Female 232 11.9 24 14 197 0.88 0.93 82.212 77 Negative 28 10.8 Alive
Male 110 12.6 40 21 48 5.82 1.16 102.544 78 Negative 20 6.9 Alive
Male 229 14.4 NA 10 192 NA 1.02 90.168 89 NA 6.0/11.0 2.8/3.9 Alive
Male 65 12.4 73 105 236 1.21 1.12 99.008 77 Negative 49 26.4 Alive
Male 221 14 42 33 521 0.38 1.41 124.644 64 NA 6/11.0 2.8/3.9 Alive
Female 145 11 NA NA 165 NA 0.86 76.024 76 NA 38/43 17.3/21.2 Alive
Male 154 7.2 88 13 43 22.14 1.33 117.572 64 Negative 48 25.5 Alive
Male 334 11.3 20 8 586 0.49 2.19 193.596 35 Negative 34 14.4 Alive
Male 135 10 45 12 160 2.84 0.8 70.72 117 NA 38/43 17.3/21.2 Alive
Male 258 13.7 33 50 205 1.07 1.31 115.804 62 Negative 16 5.5 Alive
Male 275 14.2 65 77 267 0.8 0.92 81.328 103 NA 6/11.0 2.8/3.9 Alive
Male 317 11.5 86 145 222 0.23 0.59 52.156 NA Negative 28 10.8 Alive
Male 74 12.6 73 90 176 1.49 0.9 79.56 103 Negative 44 22 Alive
Male 155 12 24 12 218 1.88 1.01 89.284 80 Negative 38 17.3 Alive
Female 153 10.9 31 20 169 0.49 0.63 55.692 NA NA Alive
Female 566 10.9 33 31 NA NA 0.75 66.3 93 NA Alive
Male 113 17.3 112 40 137 4.91 1.23 108.732 70 Negative 10 3.7 Alive
Male 39 10.3 23 14 73 3.62 1.2 106.08 70 Negative 51 28.3 Alive
Male 460 14.1 44 16 233 2.03 0.9 79.56 98 Negative 12 4.2 Death
Male 110 8.9 140 37 69 15.01 0.76 67.184 118 Negative 48 25.5 Death
Male 43 9.9 19 16 183 1.22 1.32 116.688 62 Negative 67 44 Death
Female 457 NA NA NA NA NA NA NA NA Negative Alive
Male 1138 14.7 NA NA 300 NA 1 88.4 91 Negative Alive
Male 193 12.6 19 11 225 0.99 1.18 104.312 73 NA 20/25 6.9/9.2 LFU
Female 234 11.9 23 13 190 1.41 0.96 84.864 68 NA 28/33 10.8/13.8 Alive
Female 554 11.7 NA 12 NA NA 0.73 64.532 92 Negative Alive
Female 342 11.9 47 9 206 2.81 1.08 95.472 61 NA 34/39 14.4/18 Alive
Male 75 10.2 69 39 158 3.22 0.93 82.212 93 Negative 56 33 Alive
Female 196 8.2 44 12 176 2.74 6.47 571.948 8 Negative 80 56.6 Alive
Female 487 11.1 22 12 199 1.72 1.02 90.168 60 NA 46/51 23.7/28.3 Alive
Female 196 8.9 25 14 259 0.95 1.05 92.82 63 NA 48/53 25.5/30.1 Alive
Female 123 11.5 27 7 NA NA 0.66 58.344 113 NA Alive
Female 230 8.6 NA 8 NA NA 0.85 75.14 81 Negative Alive
Male 387 13.7 16 15 NA NA 1.3 114.92 63 Negative Alive
Male 215 11.2 28 12 141 2.58 0.94 83.096 92 NA 34/39 14.4/18 Alive
Male 651 9.3 NA 8 647 NA 1.58 139.672 46 Negative Alive
Female 313 11.1 24 15 273 0.79 0.81 71.604 86 NA 28/33 10.3/13.8 Alive
Female 293 11.1 15 11 209 0.65 0.84 74.256 85 NA 28/33 10.8/13.8 Alive
Female 288 12.4 41 28 199 2.02 0.92 81.328 68 Negative 34 14.4 Alive
Male 639 NA NA NA NA NA 0.96 84.864 84 NA Alive
Male 147 14.5 73 36 91 5.88 1.26 111.384 66 Negative 10 3.7 Alive
Female 21 8 18 10 154 1.18 0.69 60.996 105 Negative 67 44 Alive
Female 339 11.7 20 8 216 1.17 1.03 91.052 64 Negative 28 10.8 Alive
Female 774 10.3 NA 14 268 NA 0.6 53.04 NA NA Alive
Male 619 15.7 22 17 NA 1.11 98.124 79 NA Alive
Male 244 17.4 27 19 147 2.53 1.19 105.196 66 Negative 24 8.7 Alive
Male 19 13.1 49 42 43 8.97 0.77 68.068 113 Negative 51 28.3 Alive
Male 298 14.2 21 12 281 1.1 1.01 89.284 83 Negative 18 6.2 Alive
Female 245 7.3 23 11 241 0.75 0.63 55.692 121 NA 44/49 22/26.4 Alive
Male 195 13.4 NA 10 212 NA 1.21 106.964 70 Negative Alive
Male 236 15.6 168 130 351 1.85 1.26 111.384 66 Negative 12 4.2 Alive
Female 235 8.4 15 10 349 0.3 0.75 66.3 103 Negative 44 22 Alive
Female 301 10.5 20 13 257 0.71 0.9 79.56 77 NA 28/33 10.8/13.8 Alive
Female 269 12.4 14 8 NA NA 0.79 69.836 91 NA Alive
Male 209 13.3 28 13 129 3.25 1.09 96.356 75 Negative 28 10.8 Alive
Male 320 14.2 NA 58 NA NA 1.04 91.936 83 NA Alive
Female 53 10.1 56 23 285 1.6 0.76 67.184 90 Negative 56 33 Alive
Female 46 11.8 48 30 NA NA 0.87 76.908 76 Negative Alive
Male 50 12.8 34 36 51 3.78 1.06 93.704 85 Negative 38 17.3 Death
Male 302 12.2 22 13 142 1.38 0.98 86.632 94 Negative 16 5.5 Alive
Male 65 9.9 71 27 15 58.3 0.9 79.56 90 Negative 66 43 Alive
Male 408 13.3 23 33 NA NA 1 88.4 87 NA Alive
Male 220 8.3 34 14 248 1.28 1.47 129.948 58 NA 50/55 27.3/32.1 Alive
Female 106 11.3 NA 8 NA NA 0.96 84.864 72 Negative Alive
Male 232 13.6 70 97 145 2.25 1.2 106.08 69 Negative 22 7.8 Alive
Female 357 7.6 NA 19 137 NA 1.2 106.08 55 Negative Alive
Male 19 12.6 63 59 72 6.04 1.06 93.704 78 Negative 51 28.3 LFU
Female 368 12.2 NA 15 NA 0.79 69.836 90 Negative Alive
Female 311 12.1 21 12 299 0.71 0.89 78.676 77 Negative 16 5.5 Alive
Female 2 5.1 32 11 271 0.21 0.41 36.244 NA NA 67/72 44/49 Death
Female 42 9.4 29 13 189 1.57 0.82 72.488 83 Negative 73 50 Alive
Female 698 11.4 20 12 229 0.71 0.8 70.72 91 Negative 22 7.8 Alive
Male 65 13.6 51 8 274 2.5 1.34 118.456 63 Negative 44 22 Alive
153 
 
 
Female 130 10.6 30 15 150 2.69 0.8 70.72 80 Negative 50 27.3 Alive
Male 123 10 124 55 463 1.3 1.58 139.672 53 Negative 38 17.3 LFU
Female 220 11.5 76 29 253 1.9 0.8 70.72 87 Negative 34 14.4 Alive
Female 49 8.7 15 23 149 1.09 0.85 75.14 75 Negative 79 55.7 Alive
Female 285 12.4 NA 11 NA NA 0.89 78.676 80 NA Alive
Male 269 13.1 54 47 206 1.49 0.7 61.88 133 Negative 22 7.8 LFU
Male 891 8.8 43 14 227 0.1 0.56 49.504 NA Negative Alive
Male 132 14.3 19 9 150 1.35 0.92 81.328 101 NA 10/15.0 3.7/5.1 Alive
Male 332 17.6 21 25 163 1.13 1.19 105.196 71 NA 06/11.0 2.8/3.9 Alive
Female 317 8 85 54 NA NA NA NA NA NA Alive
Female 641 9.8 18 NA NA NA 0.65 57.46 120 Negative Alive
Female 152 10.9 48 36 255 1.07 0.9 79.56 76 Positive 37 16.5 Alive
Male 340 13.1 NA 14 NA 1.41 124.644 56 Negative LFU
Male 406 8.3 24 7 152 2.45 1.07 94.588 81 Negative 50 27.3 Alive
Female 211 8.6 27 22 258 0.94 1.39 122.876 44 Negative 50 27.3 LFU
Male 257 12 36 12 285 0.4 0.6 53.04 NA Negative Alive
Female 26 11 30 10 216 1.58 0.95 83.98 71 Negative 57 34 LFU
Female 284 8 63 19 255 2.21 1.14 100.776 56 NA 56/61 33/38 Alive
Male 266 12.4 27 17 NA NA 1.09 96.356 75 Negative Alive
Female 210 11.1 16 9 NA NA 0.86 76.024 81 Negative Alive
Male 146 NA 30 26 287 0.84 1.02 90.168 86 Negative Alive
Female 403 10.8 34 25 440 0.17 NA NA NA NA LFU
Male 236 16.5 26 30 210 0.63 1.26 111.384 72 Negative 6 2.8 Alive
Female 196 8.7 30 17 197 1.63 0.79 69.836 84 NA 54/59 31.1/36 Alive
Female 403 7.5 79 77 196 1.7 0.85 75.14 80 NA 50/55 27.3/32.1 Alive
Female 330 10.3 16 10 203 0.72 0.96 84.864 73 Negative 28 10.8 Alive
Female 331 11.3 20 18 238 0.89 0.81 71.604 81 NA 28/33 10.8/13.8 Death
Female 313 12.5 47 17 NA NA 0.96 84.864 70 Negative Alive
Female 92 11.4 12 8 184 0.67 0.76 67.184 96 NA 50/55 27.3/32.1 LFU
Female 138 13.2 21 10 215 1.14 1.07 94.588 61 Negative 20 6.9 Death
Male 449 13.4 17 13 464 0.68 1.05 92.82 75 Negative 43 21.2 LFU
Male 118 15.8 9 19 258 0.26 1.04 91.936 87 NA 10/15.0 3.7/5.1 Alive
Female 89 10.7 16 11 NA NA 0.64 56.576 121 Negative Alive
Male 509 13.5 NA NA NA NA 1.21 106.964 68 NA LFU
Male 309 15.1 45 47 237 1 1.48 130.832 57 Negative 12 4.2 Alive
Male 528 12.7 NA 43 NA NA 1.06 93.704 81 Negative Alive
Male 7 9.3 70 25 418 0.37 0.49 43.316 NA NA Alive
Female 238 9.5 16 11 280 0.57 0.82 72.488 85 Negative 44 22 LFU
Male 153 15.7 502 150 112 16.47 1.24 109.616 67 Negative 10 3.7 Alive
Male 509 10.5 70 34 94 5.75 1.1 97.24 77 Negative 22 7.8 Alive
Male 157 14.1 34 11 170 3.86 0.9 79.56 90 Negative 10 3.7 Alive
Male 355 14.2 20 24 229 0.66 1.02 90.168 87 Negative 6 2.8 Alive
Male 106 9.9 24 15 491 0.53 1.08 95.472 80 NA 48/53 25.5/30.1 Alive
Male 159 15.4 NA NA 281 NA 0.85 75.14 105 Negative Alive
Male 353 13.7 54 53 229 1.52 0.81 71.604 109 Negative 22 7.8 Alive
Male 299 12.8 23 27 253 0.66 1.37 121.108 62 Negative 16 5.5 Alive
Male 131 15.7 37 12 236 2.08 1.48 130.832 54 Negative 22 7.8 LFU
Female 238 13.3 18 10 167 1.16 0.68 60.112 105 Negative 16 5.5 Alive
Male 283 13.7 119 198 98 2.42 1.13 99.892 82 NA 22/27 7.8/10.2 Alive
Male 72 11.5 35 10 163 2.78 0.95 83.98 93 Negative 56 33 LFU
Male 14 6.4 83 13 246 3.09 1.04 91.936 87 Negative 73 50 LFU
Male 2 10.5 54 26 161 1.32 1.12 99.008 89 Negative 51 28.3 Death
Male 135 11.6 17 10 244 0.79 1.23 108.732 71 Negative 32 13.1 Alive
Female 114 12.2 36 27 380 1 0.94 83.096 66 NA 32/37 13.1/16.5 LFU
Male 84 10.9 22 7 399 0.67 1.03 91.052 89 Negative 50 27.3 Alive
Male 86 9.9 26 10 258 1.75 1.37 121.108 57 Negative 90 65.1 LFU
Male 147 12.3 18 21 78 1.61 1.02 90.168 90 Negative 26 9.7 Alive
Female 332 14.9 52 70 257 0.94 1.31 115.804 48 Negative 12 4.2 Alive
Female 249 10.8 NA 32 NA 0.85 75.14 82 Negative LFU
Male 17 14.8 50 31 215 1.67 0.95 83.98 93 Negative 35 15.1 Alive
Male 132 14.1 20 11 202 1.52 1.04 91.936 80 NA 28/33 10.8/13.8 Alive
Male 378 11.9 NA 30 242 NA 0.64 56.576 NA Negative Alive
Female 1166 11.4 13 10 NA 0.74 65.416 99 NA Alive
Female 33 9.8 NA NA 166 NA NA NA NA Negative LFU
Male 76 11.1 39 18 312 1.24 1.25 110.5 67 Negative 50 27.3 Alive
Female 325 12.7 24 18 204 0.83 0.97 85.748 72 Negative 16 5.5 Alive
Female 444 8.1 36 12 186 1.79 0.9 79.56 77 Negative 50 27.3 Alive
Female 36 5.9 26 12 257 1.23 0.88 77.792 75 Negative 67 44 LFU
Female 540 8.1 36 15 175 2.18 1.21 106.964 52 NA 50/55 27.3/32.1 Alive
Female 774 11.3 10 12 99 1.22 0.69 60.996 99 NA 22/27 7.8/10.2 Alive
Female 372 12.3 NA 17 247 NA 0.7 61.88 104 Negative Alive
Male 257 12.6 29 28 NA 1.01 89.284 91 Negative LFU
Female 238 6.9 16 5 258 1.22 0.85 75.14 77 Negative 44 22 Alive
Male 259 14.3 NA 18 205 NA 1.23 108.732 64 Negative Alive
Male 126 10.6 16 6 278 0.99 1.11 98.124 77 Negative 32 13.1 Alive
Male 41 8.2 56 14 143 5.13 1.33 117.572 61 Negative 67 44 Alive
Female 38 10.4 45 31 341 1 1.45 128.18 42 Negative 57 34 LFU
Female 28 9.2 54 28 263 1.36 0.9 79.56 76 Negative 67 44 Death
Female 198 11.4 NA 30 NA NA 0.7 61.88 102 NA Alive
Male 143 8.3 25 20 228 0.39 NA NA NA NA LFU
Female 778 12.5 NA NA NA NA NA NA NA Negative Alive
Male 306 13.7 25 20 212 1.5 1.07 94.588 76 Negative 40 18.8 Alive
Male 51 9.5 51 29 256 1.63 1.34 118.456 62 Negative 72 49 LFU
Male 425 14.2 25 21 244 0.98 1.17 103.428 72 Negative 6 2.8 Alive
Male 581 15.4 40 62 188 0.97 0.99 87.516 91 NA 0/5 1.8/2.6 Alive
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Male 46 10.9 17 11 300 1.14 1.02 90.168 77 Negative 78 54.7 LFU
Female 308 13.1 20 15 96 2.74 1.03 91.052 60 NA 34/39 14.4/18 Alive
Male 170 12.9 21 9 274 1.15 1.09 96.356 78 Negative 20 6.9 LFU
Male 290 14.9 144 164 242 2.23 0.91 80.444 95 NA 12.0/17 4.2/5.8 Alive
Male 163 15.4 17 17 142 1.22 1.1 97.24 78 Negative 10 3.7 LFU
Male 218 11.4 38 9 169 1.2 0.68 60.112 NA NA Alive
Female 317 11.4 22 9 200 1.58 1.06 93.704 60 Negative 34 14.4 LFU
Male 275 10.6 57 15 NA NA 0.98 86.632 87 Negative LFU
Male 108 10.8 18 10 333 0.89 1.19 105.196 68 Negative 44 22 Alive
Female 233 9.3 20 10 281 0.5 1.35 119.34 52 Negative 50 27.3 Alive
Female 332 14.1 NA 16 NA NA 0.92 81.328 69 Negative Alive
Male 917 14.2 NA 22 NA NA 1.1 97.24 80 NA Alive
Male 49 11.8 29 51 NA NA 0.86 76.024 107 Negative Alive
Male 333 16.4 NA 22 NA NA 1.2 106.08 75 Negative Alive
Male 55 10.8 128 46 103 6.23 0.77 68.068 123 Negative 50 27.3 Death
Female 172 11.3 23 21 192 0.84 0.77 68.068 92 Negative 32 13.1 Alive
Female 756 11.2 NA NA NA NA NA NA NA NA LFU
Male 99 13.9 23 22 226 0.95 0.92 81.328 95 NA 38/43 17.3/21.2 LFU
Female 246 12 17 9 80 2.13 1.05 92.82 65 NA 22/27 7.8/10.2 Alive
Male 450 14.8 31 39 180 1.02 1.17 103.428 75 NA 06/11.0 2.8/3.9 Alive
Female 209 13.3 23 21 6 38.48 0.61 53.924 112 Negative 16 5.5 LFU
Male 57 10.8 NA 11 NA NA 0.94 83.096 91 Negative Alive
Male 38 10.1 19 9 276 1.03 1.12 99.008 75 Negative 51 28.3 Alive
Male 29 13 26 37 312 0.6 0.92 81.328 95 Negative 39 18 Alive
Male 174 13.8 13 15 199 0.91 0.82 72.488 104 Negative 32 13.1 Alive
Female 178 9.2 30 15 NA NA 0.81 71.604 85 NA Alive
Female 61 3.7 26 10 42 8.81 0.95 83.98 68 Negative 66 43 Alive
Female 336 12.5 NA 11 NA NA 0.77 68.068 91 Negative Alive
Female 215 11 28 19 164 1.65 0.77 68.068 87 Negative 34 14.4 LFU
Male 296 14.2 NA 15 NA NA 1.23 108.732 71 Negative Alive
Female 303 13.7 NA 34 NA NA 0.86 76.024 82 NA Alive
Female 341 12.7 NA 10 NA 0.81 71.604 82 Negative Alive
Female 64 9.4 32 15 287 1.09 0.96 84.864 69 Negative 66 43 Alive
Female 36 12.3 64 52 175 2.43 1.87 165.308 31 Negative 51 28.3 Alive
Female 312 12.8 26 13 144 1.8 1.21 106.964 54 NA 28/33 10.8/13.8 Alive
Female 263 10.3 17 11 161 1.27 0.9 79.56 74 Negative 28 10.8 LFU
Female 844 13.4 16 11 NA NA 0.95 83.98 71 Negative LFU
Male 22 10.6 60 20 169 4.53 1.09 96.356 74 Negative 63 40 LFU
Male 289 10.8 22 16 259 1.38 1.08 95.472 73 Negative 55 32.1 Alive
Male 687 14.4 NA 12 NA NA 0.88 77.792 102 Negative Alive
Male 579 15.3 NA 12 206 NA 1.13 99.892 76 Negative Alive
Male 42 12.8 34 44 188 1.06 1.15 101.66 75 Negative 39 18 Death
Male 177 12.8 31 12 NA NA 0.87 76.908 117 Negative LFU
Male 494 10.1 19 20 103 1.73 1.08 95.472 80 Negative 34 14.4 Alive
Male 46 16.6 611 297 100 17.02 1.22 107.848 67 Negative 29 11.3 LFU
Female 162 11.1 32 14 316 0.87 0.77 68.068 92 Negative 32 13.1 Alive
Male 46 12.6 30 22 128 2.15 1.12 99.008 76 Negative 45 22.9 LFU
Female 376 11.9 19 12 214 0.97 0.97 85.748 68 NA 28/33 10.8/13.8 Alive
Female 361 10.2 18 12 287 0.62 0.8 70.72 87 NA 28/33 10.8/13.8 Alive
Male 182 10 90 47 320 2.22 1 88.4 83 Negative 50 27.3 LFU
Male 60 16.5 39 29 248 1.64 1.18 104.312 68 NA 46/51 23.7/28.3 Death
Female 269 12.2 NA 25 NA NA 0.82 72.488 86 NA Alive
Female 111 10.2 17 9 NA NA 0.66 58.344 118 NA Alive
Female 493 11 NA NA NA NA NA NA NA NA LFU
Female 443 12 NA 10 NA NA 0.75 66.3 97 NA Alive
Male 384 7.4 58 17 288 1.17 1.05 92.82 92 Negative 44 22 LFU
Female 167 10 25 18 238 0.67 0.75 66.3 99 Negative 32 13.1 Alive
Male 192 13.1 46 64 99 2.03 1.19 105.196 74 NA 26/31 9.7/12.5 Alive
Female 272 12.3 12 19 NA NA 0.98 86.632 69 Negative Alive
Female 1646 9.6 121 72 316 0.27 0.49 43.316 NA Negative LFU
Female 253 12.1 78 40 310 1.95 0.83 73.372 78 Negative 22 7.8 Alive
Female 225 12 13 23 238 0.56 0.81 71.604 80 Negative 16 5.5 Alive
Female 778 12.4 NA NA NA NA 0.8 70.72 90 NA Alive
Female 318 12.2 26 15 233 1.01 0.8 70.72 87 NA 16/21 5.5/7.5 Alive
Male 202 12.8 16 7 185 1.47 1.04 91.936 82 Negative 22 7.8 Alive
Male 515 16.2 NA 29 NA NA 1.13 99.892 83 Negative Alive
Male 56 12.3 108 116 120 3.84 1.24 109.616 67 Negative 38 17.3 Alive
Male 90 17.1 46 70 163 1.21 0.94 83.096 97 Negative 28 10.8 Alive
Female 230 10.2 20 9 487 0.62 1.06 93.704 60 Negative 34 14.4 Alive
Male 31 9.5 45 44 165 2.14 1.02 90.168 82 Negative 85 61 Alive
Female 127 8.5 18 8 NA NA 0.79 69.836 84 Negative Alive
Male 260 5.6 114 68 142 3.5 1.39 122.876 61 Negative 44 22 Alive
Female 351 12.3 22 17 276 0.68 0.74 65.416 95 NA 16/21 5.5/7.4 Alive
Male 318 13.9 179 13 207 10.79 1.36 120.224 60 Negative 16 5.5 Alive
Male 421 15 NA NA NA NA 1.08 95.472 74 NA Alive
Male 447 14.7 26 16 NA NA 1.02 90.168 85 NA Alive
Female 312 11.4 18 13 199 1.15 0.9 79.56 72 Negative 28 10.8 Alive
Female 738 12.2 16 8 201 0.87 0.81 71.604 88 NA 10/15.0 3.7/5.1 LFU
Male 763 15.3 16 21 NA NA 1.2 106.08 73 NA Alive
Female 360 12.3 18 21 NA NA 0.78 68.952 97 NA Alive
Male 391 NA NA 11 NA NA 0.71 62.764 NA NA Alive
Male 103 11.2 NA 14 NA NA 0.79 69.836 122 Negative 32 13.1 Alive
Female 346 12.2 18 10 NA NA 0.72 63.648 102 NA 16 5.5 Alive
Male 447 12.2 16 15 170 1.26 1.25 110.5 64 Negative 28 10.8 Alive
